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Angiogenesis, often thought of as the first step of wound healing, is an organized series of 
events, beginning with vessel destabilization, followed by endothelial cell proliferation and 
migration, ending with vessel maturation.  Vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) have been shown to be important in vascular permeability and 
endothelial cell proliferation, and migration (early stage angiogenesis), while platelet derived 
growth factor (PDGF) and sphingosine 1-phosphate (S1P) have been shown to stimulate vascular 
stability (late stage angiogenesis).  For this reason, it was hypothesized that inducing 
angiogenesis by sequentially delivering angiogenic growth factors, controlling their presence and 
absence, would better mimic the temporal role of each factor during the progression of native 
angiogenesis in situ.  To this end, we utilized a delivery system based on porous cellulose hollow 
fibers that, for the first time, permits sequential delivery of an early stage factor followed by a 
late stage growth factor in vivo, where previous attempts have only resulted in different rates of 
delivery.  Our delivery system addresses the idea that factors involved in one stage of 
angiogenesis may inhibit other stages of angiogenesis, causing absence of one factor to be just as 
important as the presence of another factor.  Using a modified murine Matrigel plug model, it is 
apparent that delivery strategies where VEGF alone is delivered before S1P alone as well as 
delivery strategies where bFGF alone is delivered before PDGF alone, not only lead to greater 
recruitment of endothelial cells, but also higher maturation index of associated vessels.  
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Sequential delivery was also optimized by examining varying delivery schedules.  Additionally, 
the hollow fiber delivery system, was analyzed for its transport properties, where it was 
discovered that transport from the lumen of the hollow fiber to the surrounding environment was 
not only based on diffusion of the factor, but osmosis-driven convection as well.  Sequential 
delivery strategies such as this one have potential to improve wound healing strategies involving 
angiogenesis as well as other types of tissue formation that occur in a series of organized stages. 
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1.0  INTRODUCTION 
In 2010, a major aim of medicine is to generate or regenerate functional tissues to replace lost or 
compromised tissues and organs.1  The process of wound repair during injury, whether traumatic 
or surgical, is paramount to human survival.2  Diabetic ulcers and burn and trauma wounds are 
among the type of wounds receiving attention in the field of wound healing and tissue 
engineering, “an interdisciplinary field that applies the principles of engineering and life sciences 
towards the development of biological substitutes that restore, maintain or improve tissue 
function or a whole organ”.3  Many biomedical implants and scaffolds lack vasculature or an 
integrated delivery system, making the most significant barrier to wound healing and three-
dimensional regeneration a lack of delivery of nutrients, oxygen and growth factors beyond the 
limits of diffusion.4-5  Engineering large and/or complex tissues requires development of a stable 
vascular network, capable of perfusing the implant, which remains the primary limitation to 
engineering tissue of clinically relevant sizes.6 
1.1 WOUND HEALING STAGES 
Healing of any wound involves a complex, carefully regulated series of overlapping processes, 
organized into four stages: hemostasis (the cessation of bleeding), inflammation, proliferation 
(generation of granulation tissue) and scar formation or remodeling.7-8  During this process, 
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many growth factors and signals are presented to the healing tissue, coming from nearby cells 
and microvasculature.6  The temporal presence (and consequent absence) of these growth factors 
and signals are imperative to the healing process. 
Immediately following an injury, tissue factor is released from activated endothelial cells, 
initiating the blood coagulation phase of healing.9-10  This phase is characterized by disruption of 
blood vessels as well as endothelial-endothelial cell contacts11, vasoconstriction12, formation of a 
hemostatic plug and platelet activation.10  Platelet activation occurs when inflammatory growth 
factors (VEGF, bFGF, PDGF, TP, EGF, HGF, TGF-β and Ang-1) or extracellular matrix 
components of blood vessel basement membrane are exposed.9  Activated platelets then release 
the contents of their alpha and dense granules, leading to endothelial cell activation, along with 
inflammatory cell recruitment, resulting in the release of more cytokines and growth factors.9-10, 
12-13  The coagulation phase of wound healing results in the formation of a fibrin clot, which 
serves to provide a provisional extracellular matrix for cellular migration.9, 11  
Beginning about one hour after injury, the inflammation phase lasts for a few days, where 
a specialized cell group known as leukocytes (white blood cells) accumulate at the site of injury 
and clean out the wound.10  First neutrophils, a sub-group of leukocytes, passively collect at the 
wound site, making up about 50% of the cells present, playing a role in wound debridement and 
bacterial killing.10, 12-13  Neutrophils eventually migrate to the surface of the wound, making 
room for bone marrow derived monocytes.13  These monocytes differentiate into macrophages, 
another sub-group of leukocytes10, which bind to the extracellular matrix via integrin receptors11 
and secrete growth factors that facilitate the next phase of healing.12 
The proliferative phase of healing begins around the third day following an injury and 
lasts for about three weeks.10  This phase is marked by the production of collagen and scar tissue 
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(to replace fibrin, provisional matrix and granulation tissue) by fibroblasts.10-11  As collagen is 
produced, wound contraction occurs and tissue integrity is restored by fibroplasias, 
neovascularization and re-epithelialization.12  Neovascularization is very important during this 
phase, as the formation and integration of new blood vessels allows oxygen and nutrient delivery 
to the healing tissue, which is necessary for cellular metabolism.4-5, 11  Without 
neovascularization, healing tissue becomes necrotic and the wound will not heal. 
The last phase of wound healing, the remodeling phase is a slow, dynamic process (can 
last up to six months), characterized by equilibrium between collagen synthesis and destruction, 
giving the scar its tensile strength.10, 12  The degradation of collagen in the wound is controlled 
by several proteolytic enzymes (matrix metalloproteinases), which are secreted by macrophages, 
fibroblasts and endothelial cells.11  Wound sites typically only gain about 20% of their final 
strength in the first three weeks following an injury and may never reach 100% of the original 
strength prior to the injury.14 
1.2 CLINICAL WOUNDS AND TREATMENTS 
1.2.1 Wound types 
The need for an improvement in clinical wound treatment is evidenced by the 8 million patients 
per year that present with a significant wound, including burn wounds and skin ulcers caused by 
pressure, venous stasis or diabetes, where there is no “gold standard” treatment.11, 15  With burn 
wounds accounting for 1.25 million of these patients16, another specific area of trauma wounds 
that is the focus of wound treatment research is battle field wounds.  Battlefield injuries are at 
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their highest, despite the fact that battlefield fatalities are less than half of what they have been 
for previous wars.17-18  These injuries are typically associated with profuse bleeding, pain, 
inflammation and infection, leading to increased pressure, reduced blood flow (ischemia) and 
eventually a condition known as compartment syndrome.3, 16  Proper re-establishment of blood 
flow in a wound has potential to eliminate compartment syndrome and set the stage for 
regeneration. 
Skin ulcers, a type of non-traumatic wound, are also a cause for wound treatment.  These 
wounds are prevalent in the diabetic population and are the major cause of non-traumatic lower-
extremity amputations – a diabetic patient loses a foot or a leg to a diabetic ulcer every 30 
seconds in the world.12  Diabetic patients commonly experience a reduction in growth factor and 
receptor expression, as well as peripheral arterial disease.12, 19-21 This combination leads to 
neuropathy, ischemia and poor nutrient supply, depriving patients of sensation, causing 
unrecognized trauma.10, 12  These resulting infection is associated with abnormal or reduced 
growth factor expression, leukocyte abnormality and microangiopathy, which all lead to poor 
wound healing.10, 12 
Ulcers of the skin can also be caused by insufficiency of the venous valves, known as 
venous stasis, causing blood to pool and hydrostatic pressure to increase.  The pressure on the 
capillary beds causes the gap junctions between the endothelial cells to widen.  The widening of 
the gap junctions causes a decrease in oxygen, nutrient and cytokine levels, leading to tissue 
breakdown, ulceration and infection.10  Skin ulcers tend to be chronic, resulting from impeded 
neovascularization and a high bacterial burden,10 and more than half of chronic wounds that 
persist for more than a year remain resistant to traditional therapies.22-23 
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Another type of skin ulcer is an arterial ulcer, caused by poor distal perfusion to a limb.  
These ulcers often lead to progressive hypoxia, ischemia, necrosis and skin breakdown, and are 
prevalent in patients with peripheral artery disease, where the hypoxia feedback loop responsible 
for initiating blood vessel growth when oxygen levels are low does not perform properly.24  
Patients without normal angiogenic capacity could benefit from clinical wound healing methods 
designed to stimulate angiogenesis. 
1.2.2 Current treatment options 
Currently, a common treatment for non-healing surface wounds is skin grafting,16, 22 but in many 
cases the skin and underlying tissue is so greatly damaged that there is no available site from 
which autologous tissue can be taken.  In the case of non-surface wounds, a clinically accepted 
therapy is transplantation, but the need for transplants is far greater than the supply.25  Allografts 
and xenografts typically lead to immunorejection and/or pathogen transmission and subsequent 
complications associated with immunosuppressive therapies.4  Another common treatment is 
sharp debridement of the wound to healthy, well-vascularized tissue, combined with removal of 
necrotic debris, foci of infection and edema.  This treatment helps to reestablish the dynamic 
process of normal wound healing.10, 12  In 1997, the use of Regranex® (Ortho-McNeil 
Pharmaceutical), or becaplermin gel, was approved by the Food and Drug Administration as a 
topical wound ointment for the use of healing ulcerations (in conjunction with standard wound 
healing practices) in the feet of chronic wounds.10  To date, becaplermin gel as also be used on 
irradiated wounds and chronic orbital ulcers after exteneration.2  The ointment, applied once 
daily, contains platelet derived growth factor (PDGF) at a concentration of 100µg/g gel,12 
promoting chemotactic recruitment and proliferation of cells involved in wound repair.10  More 
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recently, becaplermin gel has also been shown to induce bone healing in craniofacial wounds.2  
Additionally, cell-based therapies such as a human fibroblast-derived dermal substitute, a human 
fibroblast-derived temporary skin substitute and an allogenic bilayered cultured skin equivalent, 
are commercially available tissue engineered solutions to chronic wounds.26   Although there 
have been many recent advances, randomized trials and studies that evaluate the efficacy of these 
advancements have been less than ideal, leaving the “gold standard” for wound healing yet to be 
discovered.27-29  The desire to create more effective and practical therapies for tissue loss and 
functional deficits have inspired the field of tissue engineering.25 
1.3 TISSUE ENGINEERING AS A TREATMENT FOR WOUNDS 
The most recent definition of tissue engineering, as defined by Williams in 2006, is the creation 
of new tissue for the therapeutic reconstruction of the human body by the deliberate and 
controlled stimulation of selected target cells through a systematic combination of molecular and 
mechanical signals.30  Although tissue engineering is a viable solution to many problems in 
healing, there are many limitations that prevent these therapies from becoming clinically 
relevant.  Mainly, these limitations are biocompatibility and a lack of blood supply, where 
restoration of new blood vessel growth is important in all regenerative processes.1, 4-5, 31  In an 
effort to address the lack of blood supply, many researchers have attempted grow or assemble 
vessels ex-vivo and then implant them into the body.  While large (>1mm diameter) and 
intermediate vessels (50-150µm diameter) are sometimes possible to engineer32-33, smaller 
vessels such as capillaries are notoriously difficult to engineer, due to their required degree of 
self assembly and self-organization.34  One example of research in this field is the co-culture of 
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endothelial and mural cells with the overall goal of inducing cells to form a functional vascular 
network ex-vivo that will promote survival of the implanted tissue.35-36  However, this attempt, 
as well as other similar attempts have led to immature vessels that have a limited potential to 
integrate with host vasculature37 and are prone to regression.38 These vessels have also been 
shown to be more fragile, leaky and lead to edema after implantation.39  Additionally, the 
implantation of a foreign cell population, when the patient’s own cells cannot be used, invariably 
leads to immunological responses, causing thrombosis and occlusion upon implantation.16  
Overall, success of prevascularization on the capillary level has not been achieved beyond 1mm, 
thus not challenging oxygen and nutrient diffusion limitations.34 
In an effort to avoid immune response, some researchers are attempting to promote 
invasion of host vasculature into an implant by combining a scaffold with drug release, 
functional matrices or surgical techniques.  One method is the creation of channels similar in size 
to microvasculature and favorable for endothelial attachment with the idea that endothelial cells 
will invade and line the channels, forming vessels.  An example of this uses 
microelectrochemical systems (MEMs) to etch channels into a silicon wafer, which can then be 
used as a mold for a poly(glycerol sebacate) scaffold.  When the scaffolds are bonded together, 
capillary networks are created which can then be endothelialized in vitro under flow conditions.  
However, these flow conditions are not present upon implantation in vivo.40  Another example 
involves the seeding of endothelial cells onto collagen gels that are molded around stainless steel 
needles.  The vessels formed as a result of this technique show normal microvascular functions 
including reactivity to cytokines, but they lack a basement membrane, which is necessary for 
maintenance of vessel integrity once implanted in vivo.32  Microchannels have also been created 
in a polyethylene diacrylate hydrogel, resulting in host tissue infiltration within the actual 
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channels of the implant.  Additionally, VEGF localization to the host derived tissue was 
observed, but host tissue infiltration into the hydrogel itself was not seen.41  Tissue engineering 
of implants larger than 1mm requires development of a stable vascular network, capable of 
perfusing the implant.  This challenge remains the primary limitation to engineering tissue of 
clinically relevant sizes.6 
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2.0  NEOVASCULARIZATION 
Formation of new blood vessels, or neovascularization, is essential to wound healing and tissue 
growth, specifically so that the oxygen and nutrient supply can be reestablished to the wounded 
or growing tissue.10, 42-45  Additionally, inflammatory cells that are necessary for wound repair 
require the interaction with and transmigration through the blood vessel basement membrane to 
enter the site of injury.46  It is believed that techniques to promote and accelerate this process will 
have a tremendous impact on public health.47  As just a few examples, therapeutic induction of 
neovascularization can be used to treat ischemic left ventricular dysfunction (as a result of 
coronary artery disease)47, battlefield wounds17-18, diabetic ulcers and tissue defects.48 
2.1 ANGIOGENESIS 
Perhaps the most well known and well studied type of neovascularization is angiogenesis, 
which is defined as the growth of new blood vessels from pre-existing vessels.49  Angiogenesis 
can be either physiological or pathological, where physiological angiogenesis is a normal and 
vital process in growth and development as well as wound healing and pathological angiogenesis 
is a fundamental step in the transition of tumors from a dormant state to a malignant one.50  The 
cells and biological structures that make up blood vessels, as well as the biomolecules involved 
in the process of physiological angiogenesis will be discussed further in Chapter 3.0   
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Healing of any wound, other than non-excisional wounds, cannot occur without 
neovascularization, which is generally considered to occur during the proliferative phase of 
wound healing.  Clinically, new capillaries first become visible 3-5 days following an injury.51  
However, many signals that initiate angiogenesis also occur in the inflammatory phase.46  As 
new blood vessels form, endothelial cells that line the vessels control oxygen and nutrient 
transport across the vessel wall to the healing tissue,46 as well as organize and regulate healing.  
These endothelial cells also provide the provisionally matrix necessary for the proliferative phase 
of healing,51 where blood vessels represent 60% of the mass of granulation tissue.52  Impaired 
granulation tissue formation is a hallmark of chronic non-healing wounds. 
2.2 VASCULOGENESIS 
Another way that vessels are formed in the body is through vasculogenesis, which is defined as 
de novo formation of immature cords from the differentiation of progenitor cells.  These cords go 
through tubulogenesis and mature into vessels.10  The process of vasculogenesis is essential in 
adult neovascularization as well as fetal vessel formation.  Fetal vasculature formation begins 
with primitive cells of mesoderm origin (hemangioblasts) that form blood islands, which 
eventually differentiate into endothelial cells.10 
Circulating endothelial progenitor cells derived from bone marrow (marked by CD133 
expression), thought to be involved in adult vasculogenesis, were isolated for the first time in 
1997.10  These cells were shown to contribute to the re-endothelialization of injured vessels and 
ischemia-induced neovascularization, improving endothelial cell function.53  These cells 
represent an important endogenous repair mechanism by which the body maintains vessel 
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function, where several clinical studies have shown a decreased number of these cells in some 
pathological conditions, specifically coronary artery disease.10, 53  Various stimuli, such as 
vascular trauma, cause the mobilization of these cells from the bone marrow into circulation.53  
Once at the site of injury, the progenitor cells exert their function by activating the local 
endothelial cells and/or differentiating into mature endothelial cells that integrate the damaged 
vessels, thereby contributing to endothelial repair.8, 53  Studying adult vasculogenesis allows 
researchers to make decisions about how to induce endothelial progenitor cell migration in a 
wound site. 
Mobilization from the bone marrow into circulation is thought occur via cytokine 
mediated pathways, specifically in response to VEGF, as observed in burn and coronary artery 
bypass grafting patients.53  In vitro, multipotent adult progenitor cells (CD133 positive), isolated 
from the bone marrow differentiate into endothelial cells, marked by CD34 and VEGF-R2 
expression. when cultured on high density fibrinogen with VEGF.10  Additionally, an increase in 
VEGF correlates with a rise in circulating early endothelial progenitor cells within six hours of 
burn and coronary artery bypass patients, returning to normal within 48-72 hours.10  Once at the 
site of vascularization, early progenitor cells become late progenitor cells by losing expression of 
the transmembrane glycoprotein CD133 and gaining another membrane protein CD31, the 
glycoprotein Von Willebrand factor and transmembrane vascular endothelial cadherin 
expression.10  Finally, there is also evidence the vasculogenesis is contributed to by circulating 
endothelial progenitor cells, which naturally home and integrate into sites of physiological vessel 
formation in vivo.54 
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2.3 VASCULOGENESIS AS A THERAPY 
Vascular and cardiac diseases encompass a variety of pathological, structural and functional 
changes in the cellular architecture of blood vessels and heart muscle.55  Traditional approaches 
to such pathologies have been pharmacological agents or surgical intervention, but with 
regenerative medicine at the front of therapeutic medical research, a paradigm shift has occurred, 
moving focus to other approaches such as cell therapy.56  Animal studies have provided evidence 
of the role of endothelial progenitor cells in postnatal vasculogenesis and their potential to treat 
complications associated with tissue ischemia.56-57  Bone marrow-derived progenitor cells that 
are phenotypically CD34 and Flk1 positive, as well as CD133 positive cells, have been reported 
to contribute to tissue repair by differentiating into both endothelial cells and vascular smooth 
muscle cells, as well as other cell types. 58  These cell types have been evaluated for their 
benefits in treating acute myocardial infarction, limb ischemia59-62 and dilated cardiomyopathy.58-
60  Various studies have been performed to test the clinical efficacy of endothelial progenitor 
cells in patients with cardiovascular disease.  These include the mobilization of these cells with 
pharmacologic agents in patients with heart disease and harvesting of cells from the circulation 
and bone marrow for autologous reinfusion in affected patients.58  Results from these trials have 
been mixed and not as successful as animal studies, likely due to the variation in the definition of 
human endothelial progenitor cells and the resulting heterogeneity in cell populations used in the 
treatments.58 
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2.4 BLOOD VESSEL WIDENING, SPLITTING AND EXPANSION 
Other methods the body uses to react to decreased blood flow is arteriogenesis, the development 
of collateral circulation by the widening of small vessels10 and intussusceptions (splitting) of one 
vessel into two.9  Arteriogenesis is induced following the occlusion of a major artery and 
consequent hemodynamic and mechanical effects on the collateral vessel wall.  These effects 
occur with increasing blood flow velocity due to the low pressure at the reentrant site of the 
collateral vessel.63  A variety of different cytokines act by stimulating endothelial and smooth 
muscle cell proliferation and monocyte migration or recruitment and activation (MCP-1, bFGF, 
TGF-β, VEGF, and GM-CSF).63  Several clinical trials have been published in that field to 
suggest the feasibility and safety of treatment with such cytokines or their genes.  However, the 
results indicate that further studies are needed before proarteriogenic therapies are ready for 
clinical application.63 
 All of these processes are essential in both embryogenesis and wound healing, but also 
play a role in several pathological processes such as tumor vascularization, diabetic retinopathy, 
psoriasis and rheumatoid arthritis.9  Perhaps the most common form of neovascularization in 
adults is angiogenesis, the process by which endothelial cells sprout from preexisting blood 
vessels and then migrate and proliferate to form a cord-like structure.10 
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3.0  ANGIOGENESIS 
Angiogenesis is an organized series of events, beginning with vessel destabilization, followed by 
endothelial cell proliferation and migration, and lastly vessel maturation.9  During these events, 
different angiogenic growth factors become important at different points in time,64 forming a set 
of stage-specific “instructions” to guide the process.  Chapter 6.0 will describe this process in 
greater detail.  The following sections describe the cells and proteins that make up blood vessels, 
as well as the growth factor involved in angiogenesis. 
3.1 ANATOMY OF A BLOOD VESSEL 
3.1.1 Endothelial Cells 
Blood vessels are complex structures comprised of endothelial cells, mural cells and a basement 
membrane (Figure 1).  Endothelial cells are the cells that line the interior surface of blood 
vessels, serving as the interface between the blood and the rest of the vessel wall from the largest 
artery to the smallest capillary.  As a monolayer, these cells control the passage of molecules and 
the transport of white blood cells into and out of the bloodstream.  These cells can come from 
other endothelial cells or endothelial progenitor cells that circulate in the bone marrow or blood 
and are often identified by CD31, and/or von Willebrand factor.54  In quiescent vessels, 
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endothelial cells are polarized with a luminal and abluminal surface, acting as a barrier and a 
non-thrombogenic surface.10  Endothelial cells express VEGF receptors, which bind VEGF 
produced by vascular pericytes, as well as secrete anti-apoptotic factors.  Both of these actions 
are essential to their survival. 9, 65-66 
3.1.2 Mural Cells 
Mural cells associated with blood vessels can be vascular pericytes (on smaller vessels) or 
smooth muscle cells (on larger vessels).65  These cells serve to reinforce tubular endothelial 
networks, stabilize vessels by enhancing endothelial cell-cell contact, produce extracellular 
matrix proteins and regulate luminal diameter.10  Normal pericytes are embedded into the 
basement membrane of capillaries as either solitary cells or a single cell layer.65  In veins and 
arteries, vascular smooth muscle cells form a single or multiple cell layer around the vessel to 
mediate vascular tone and contraction.65  Vascular mural cells are commonly identified by alpha 
smooth muscle actin, regulator of G protein signaling 5 and platelet derived growth factor 
receptor.  Mural cells that associate with vasculature are necessary for vessel maturation, 
stabilization and quiescence.65  Therefore, mural cells are inherently scarce at the site of 
developing vascular sprouts and are recruited to the site of newly forming vessels by 
biomolecules such as PDGF and sphingosine-1-phosphate.65  Contacts made with neighboring 
endothelial cells help coordinate intracellular signaling to prevent vessel leakage and inhibit 
proliferation.65 
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3.1.3 Basement Membrane 
The basement membrane serves as a physical barrier conferring adhesion and stability of the 
vessel.  Collagen IV and laminin 1 comprise a large portion of the extracellular matrix proteins 
present in the basement membrane, which is also a reservoir for heparin binding growth factors 
such as VEGF and bFGF.9  When the basement membrane is degraded, for example following an 
injury, sequestered growth factors are released, creating space for endothelial cells to migrate 
and secrete new basement membrane.9 
 
 
 
Figure 1.  Vessel cross section. 
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3.2 ANGIOGENIC GROWTH FACTORS 
There are many growth factors involved in the process of angiogenesis, which constitute a 
complex family of polypeptide molecules and exert specific biologic reactions through the act of 
binding to cell surface receptors.1   
3.2.1 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a 34-46kD secreted, heparin-binding8 glycoprotein 
with a disulphide homodimer bond, with VEGF165 being the predominant isoform in humans.9  
VEGF was first discovered when isolated from tumor lysates, and shown to be involved in the 
initiation of angiogenesis67 and endothelial cell proliferation,65, 68 and is one of the most widely 
studied angiogenic growth factors.69  Specifically, VEGF promotes angiogenesis, providing 
chemotactic factors for inflammatory cells, recruiting endothelial progenitor cells from the bone 
marrow and upregulating other angiogenic factors.8  It is released from activated platelets as well 
as activated macrophages following an injury.8  The VEGF/VEGF-receptor signaling system (5 
VEGFs, 3 VEGFRs) on endothelial cells is perhaps the most important signaling system for 
angiogenesis.10  It has been shown that blocking the action of VEGF (with a monoclonal 
antibody to either VEGF or its receptor) blocks the process of angiogenesis.9  Additionally, 
under hypoxic conditions, VEGF production by vascular pericytes is upregulated8 from a 
baseline maintenance level.65  This upregulation leads to dissociation of the endothelial cells and 
vascular pericytes, allowing angiogenesis to initiate.65  Other angiogenesis actions in which 
VEGF is involved include vasodilation and increased permeability of the endothelial barrier8, 65 
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In vitro, VEGF has been shown to explicitly stimulate the proliferation of human 
umbilical vascular endothelial cells (HUVECs) and not smooth muscle cells,8 displaying the 
specificity in the action of VEGF. Additionally, VEGF has been shown to induce upregulation of 
matrix metalloproiteinase-1 from smooth muscle cells,8 which in turn leads to basement 
membrane degradation.  In vivo, VEGF has improved skin graft survival in rats8 and also 
reduced pericyte coverage on nascent vascular sprouts through inhibition of PDGFR signaling in 
mural cells.65  A reduction in pericyte coverage leads to less mature and less stable vessels.  In 
combination with bFGF, VEGF has increased angiogenesis in a rabbit hindlimb ischemia 
model.8  However, it has also been shown that angiogenesis induced by the delivery of 
exogenous VEGF leads to leaky, immature vessels,9 indicating that perhaps other growth factors 
are necessary for complete angiogenesis.  The importance of VEGF in development has been 
documented, showing that a 50% reduction in VEGF expression results in embryonic lethality.70  
3.2.2 Basic fibroblast growth factor 
Basic fibroblast growth factor (bFGF) is an 18kD protein that, like VEGF, is released into a 
wound site from activated platelets and marcrophages.8  As a strong mitogen for many cell types, 
bFGF plays a role in neuronal signaling, inflammation, hematopoiesis, tumor growth and 
invasion, as well as angiogenesis.9  Basic FGF is also found bound to heparin sulfate 
proteoglycans in the extracellular matrix and is released during ECM-breakdown.9  In addition to 
inducing angiogenesis as a result of its chemoattraction effect on smooth muscle and endothelial 
cells, bFGF aids in the proliferation of fibroblasts and epithelial cells.8  Specific to endothelial 
cells, bFGF induces proliferation, chemotaxis and urokinase type plasminogen activator activity, 
VEGF and VEGFR2-upregulation, all the while inducing a pro-angiogenic phenotype.9, 71-72  
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Furthermore, monoclonal antibodies against bFGF has been shown to inhibit angiogenesis in a 
similar fashion as antibodies to VEGF.9 
In vitro, bFGF seems to have important interactions with VEGF, where bFGF activity has 
been shown to be regulated by the upregulation of VEGF.9  Additionally, bFGF has been shown 
to upregulate VEGF expression in rabbit vascular smooth muscle cells in a concentration 
dependent manner.8  In vivo, bFGF has been shown to enhance collateral blood flow when 
administered to ischemic coronary artery72, limb and heart.73  Additionally, four weeks following 
removal of the right femoral artery in rabbits, an increased number of arterioles, tissue perfusion 
and vascular density were observed.8   
3.2.3 Platelet derived growth factor 
Found at the surface of healing wounds2, platelet derived growth factor, a 30kD dimer, is a 
prominent cytokine active in all stages of the healing process10 and one of the most potent 
inducers of angiogenesis.9  It is a known powerful chemoattractant and mitogen, exerting action 
on fibroblasts, neutrophils, monocytes, smooth muscle cells and endothelial cells.2, 12  PDGF is 
mainly secreted by the platelets’ alpha granule74, but also produced by other cells involved in 
healing (macrophages, endothelial cells, fibroblasts, keratinocytes)9, 12, stimulating mitogenicity 
and chemotaxis of more fibroblasts, neutrophils and macrophages2.  More specifically, PDGF, 
stimulates macrophages to produce and secrete other growth factors for various phases in the 
healing process and fibroblasts to upregulate production of fibronectin, collagen, proteoglycans, 
hyaluronic acid and collagenase.2 
PDGF exerts its cellular effects by binding and activating PDGF receptors, leading to 
stimulation of cell growth as well as changes in cell shape and motility.2  This action induces 
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reorganization in the actin filament system and stimulates chemotaxis.2  PDGF receptors can be 
found on many cell types (fibroblasts, smooth muscle cells, microvascular endothelial cells), 
leading to cellular proliferation and migration, when bound to PDGF (ex: PDGF homodimer 
PDGF-BB binding the β form of the receptor).9  Genetic deletion of PDGF-BB in mice has been 
shown to lead to a reduction in pericyte coverage of blood vessels, resulting in defective 
endothelial cell junction, endothelial hyperplasia, microvascular leakage, vessel dilation, poor 
capillary flow and hemorrhage.65  It is believed that PDGF is responsible for the promotion and 
stabilization of mature blood vessels through the recruitment and support of mural cells.67, 75-76  
This action is thought to occur via the activation of the stromal derived factor-1A/CXCR4 axis.65  
Because of its evident pluripotency, PDGF has become the first growth factor to be used 
clinically for the healing of wounds, specifically diabetic foot ulcers, known as becaplermin gel. 
3.2.4 Sphingosine 1-phosphate 
Sphingosine-1 phosphate (S1P), a pleiotropic autocrine and paracrine signaling sphingolipid77, is 
stored in platelets and released upon activation, following an injury.78  S1P is produced 
intracellularly in organelles and the plasma membrane, and is then secreted.79-80  It is also known 
for recruiting vascular pericytes to a vessel wall,65 thus  promoting vessel stabilization in vivo.74, 
78  As an endogenous lipid, S1P exerts pleiotropic effects including cell migration, cell 
proliferation, and cell survival in diverse cell types (including endothelial cells) through specific 
G-protein-coupled receptors.81-82  Endothelial cells largely express the S1P receptors S1P1, S1P2 
and S1P3, which mediate stimulation of endothelial cell proliferation, migration, and capillary-
like tube formation in vitro.83-84  These receptors appear in varying ratio, depending on what 
vessel type on which the endothelial cell appears (arteries, capillaries, veins, lymphatics).85  S1P 
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has been shown to stimulate endothelial proliferation, migration and angiogenesis, protect 
against apoptosis and control vascular permeability.86-87  In vitro, S1P induces endothelial cell 
proliferation as well as serves as a potent chemoattractant for endothelial cells.88  Also in vitro, 
S1P has been shown to reduce endothelial cell permeability85, likely due to the ability of S1P1 
and S1P3 to strengthen endothelial cell junctions.89-91  It has also been shown to promote directed 
migration, vascular differentiation and formation of capillary networks, on complex extracellular 
matrices.83, 92  
The S1P1 receptor on endothelial cells has been shown to be imperative in the 
recruitment of vascular pericytes, ensuring vessel maturation.92  When endothelial cells are 
exposed to S1P in vitro, their angiogenic effects (migration, proliferation and tube formation) are 
mostly due to the inability of pericytes and smooth muscle cells to form the vascular sheath and 
thus stabilize the nascent vessel. Remarkably, this process is controlled by the endothelial S1P1 
and not smooth muscle S1P1 because both the global and endothelial-specific S1P1 knockout 
exhibit the same lethal phenotype caused by vascular hemorrhage.93  S1P1-deficient mice have a 
marked endothelial-cell defect that diminishes the structural integrity of their blood vessels and 
results in embryonic lethality.77  In vivo, S1P has a beneficial effect on ischemia-induced 
myocardial damage through inhibiting leukocyte infiltration and apoptosis.94 
3.2.5 Other growth factors involved in angiogenesis 
Other growth factors that are involved with angiogenesis include placenta growth factor (PlGF), 
epidermal growth factor (EGF), Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2).  PlGF is 
expressed in placenta as well as tumors and binds with VEGF.  It has been shown to control the 
bioactivity of both VEGF and bFGF in vivo.9  EGF is secreted by platelets, macrophages and 
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monocytes, but does not seem to have a direct effect on vascular endothelium.  However, EGF 
plays a role in tumor proliferation, metastasis, apoptosis, angiogenesis and wound healing.9  
Angiopoietin-1 (Ang-1) binds the cell surface receptor TIE2, which is expressed exclusively on 
endothelial cells.  In highly vascularized tissues, Ang-1 is constitutively and widely expressed, 
where it binds extracellular matrix proteins and is released when endothelial cell binds at the 
same site.  Ang-1 can induce endothelial cell adhesion, spreading, focal contact formation and 
migration, but cannot trigger angiogenesis alone.  It is involved in vessel maturation and 
quiescence, and inhibits activating effects of VEGF on endothelial cells.9  Ang-2 is a natural 
antagonist of Ang-1 with similar binding affinity to the cell surface receptor TIE2.  It is 
expressed in the ovary, placenta and uterus, which are all organs with constant blood vessel 
growth and regression.  Ang-2 can be up-regulated by VEGF, bFGF and hypoxia, while down-
regulated by Ang-1, TGF-β and itself.  Like Ang-1, Ang-2 cannot trigger angiogenesis alone.9 
There are also a number of growth factors responsible for inhibiting angiogenesis and 
blood vessel growth.95-96  These factors can be found circulating in the bloodstream or stored in 
the extracellular matrix.  In normal conditions, these factors govern blood vessel homeostasis, 
but when an injury occurs, angiogenic stimulators are released, favoring blood vessel growth.96 
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4.0  ANGIOGENESIS THERAPIES FOR TISSUE REGENERATION 
Impaired circulation (clogged or lack of vasculature) is an underlying pathological feature in 
peripheral arterial disease, ischemic heart disease and chronic wounds.  Patients exhibiting these 
maladies, combined with burn and trauma wound patients, create a need for angiogenic therapies 
to help regenerate tissue, restore perfusion, reverse ischemia and accelerate repair.  Three 
common strategies, or fundamental “tools”, are often employed when addressing the problem of 
tissue regeneration and engineering of any tissue or organ.1  The first strategy, induction, entails 
delivery of growth factors that promote a specific, desired host effect.  The second strategy, 
conduction, involves the implantation of an acellular biomaterial or scaffold that provides 
structural support for the ingrowth of the desired healthy host cells.  The third strategy is 
transplantation of cells that participate in tissue-specific regeneration.  These strategies, known 
as the “tissue engineering triad” can be used alone or in combination with each other.97  
Coordinated interactions with soluble growth factors, other cells and extracellular matrices 
define a local microcellular environment that cells sense, regulating their cellular processes.25 
4.1 INDUCTION VIA GROWTH FACTORS 
Cell fate is influenced largely by the biomolecules they sense in their local environment through 
cell surface receptors.  Biomolecules known as growth factors are soluble-secreted signaling 
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polypeptides capable of instructing specific cellular responses in a biological environment.  
Triggering responses can result in a very wide range of cell actions, including cell survival, and 
control over migration, differentiation or proliferation of a specific subset of cells.98  It is widely 
accepted that the incorporation of growth factors can facilitate proper growth in tissues that 
cannot heal on their own.99  It is increasingly clear that growth factors are typically multimodal, 
exhibiting different mechanisms of action, depending on the concentration, exposure time and 
phenotype of the target cells.25 
Growth factors action is initiated by binding to specific transmembrane receptors on the 
surface of target cells that facilitate communication from outside of the cell to its cytoplasm and 
nucleus.  The typical response to growth factor binding to its receptor is receptor activation by 
phosphorylation of the intracellular portion of the receptor, followed by signal transduction 
through molecular pathways in the cell cytoplasm to the nucleus.  The level of expression of 
these receptors partially controls the level of response from the cell.100 
As regulators of chemotactic, mitogenic, morphogenic, apoptotic and metabolic effects, 
growth factors play a crucial role in information transfer between a cell population and their 
microenvironment.25, 101  With an improved understanding of the critical pathways involved in 
angiogenesis, the role of growth factors can be used to advance therapies in the clinic.  Delivery 
of either bFGF or VEGF has shown limited success, ultimately leading to weak, leaky vessels.9  
Specifically, VEGF delivery has been shown to be insufficient for the formation of complex, 
mature vasculature, lacking pericyte coverage and stability.102-103  Also, bFGF induced tubules 
tend to regress over time, in the absence of other angiogenic signals,104 likely due to the fact that 
bFGF only acts on the formation of tubular structures and not the supporting anatomy.105  
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However, individual growth factor based therapeutics for angiogenesis induced wound healing 
has had limited success.43, 106 
The limitations associated with delivery of growth factors include a short half-live in 
vivo, temperature sensitivity and the need for refrigerated storage.  An alternative approach to 
growth factor delivery is gene therapy, where a plasmid DNA encoding for the desired protein is 
injected into the wound bed temporarily increases the local expression of the protein.  While 
protein delivery relies on the delivery and activity of the protein, gene delivery also relies on 
cellular production and secretion of the encoded protein.1  This process results in delayed 
availability of the protein, when compared to protein delivery and effectiveness for only three 
weeks107, but solves the problem of protein destabilization when incorporated with a polymer.  
The biggest challenge in this approach is to overcome the low efficiency of transfection, which 
results in low levels of protein production.108 
Some clinical trials have been performed that are based on either delivery of recombinant 
growth factors or genes that encode for those growth factors.   In a non-viral gene therapy for 
peripheral arterial disease patients, a gene encoding for human VEGF was used.109  Plasmid was 
injected into the calf or distal thigh twice: once at the initiation of the study, and again four 
weeks later.109  These injections led to an increase in VEGF gene expression levels, collateral 
vessel development, distal blood flow and healing.109  Recombinant bFGF has been studied when 
delivered via an intra-arterial diffusion to the legs of peripheral arterial disease patients.110  A 
trend of increased walking time, ankle-brachial index and quality of life, was observed in 
patients receiving treatment compared to the placebo, but a statistical difference was not 
observed.110 
 26 
Treatment of delayed and chronic wounds has also been explored.   VEGF has been 
reported to enhance healing and angiogenesis in ischemic ulcers, but capillaries are immature 
and leaky,10 similar to the delivery of exogenous VEGF in the protein form.  Recombinant 
human keratinocyte growth factor-2, which stimulates endothelial cells, was administered as a 
topical spray to venous insufficiency ulcers, in conjunction with standard compression therapy in 
a phase II clinical trial.111  A statistical difference was observed when growth factor treated 
ulcers were compared to ulcers only treated with compression therapy.111  In 1997, becaplermin 
gel was the first growth factor based therapy for the promotion of angiogenesis in non-healing 
wounds, specifically full thickness diabetic foot ulcers.  Becaplermin gel has also been used in an 
off-label fashion to treat venous stasis ulcers, arterial insufficiency ulcers, burns, ischemic ulcers, 
trauma wounds and pressure ulcers.112  To date, becaplermin gel still stands alone, however it is 
only effective in 30% of the wounds it is used to treat.10 
4.2 CONDUCTION VIA BIOENGINEERED SCAFFOLDS 
Polymer systems used for angiogenic conduction attempt to mimic key aspects by which the 
extracellular matrix interacts with the cells.  Synthetic polymers are readily available and exhibit 
well-defined chemical and physical characteristics, allowing for reproducibility of scaffold 
properties.1  These polymer systems are often combined with growth factor delivery or induction 
approaches so that the cells are attracted to the site, but also have structural support for migration 
and attachment.  Polymer matrices with relevant modifications for growth factor presentation 
and release are attractive platforms for delivery substrates.  Bioactive growth factors can be 
chemically immobilized or physically encapsulated into polymer matrices, preventing 
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denaturation.  Their release is then controlled by the degradation rate of the scaffold, their 
diffusion through the polymer or external triggers.113-114  Controlling the degradation kinetics of 
polymer-based delivery systems enable one to control the release profile of growth factors, 
resulting in optimized concentrations of growth factors, which is one of the  main goals of these 
systems.98 
In addition to designing scaffolds that release growth factors to control chemotactic 
responses of cells, the physical properties of the scaffold itself can contribute to subsequent 
cellular growth factor secretion and related cell signalling.67  Research shows that physical 
parameters, such as shape, elasticity, hardness, stiffness, pore size, elastic reversibility and 
degradation rate of matrices, can alter cellular processes.115-116 
Some bioengineered scaffolds include prevascularization, where endothelial cells are 
seeded ex vivo and implanted.  Prevascularization of tissue involves co-culturing endothelial and 
mural cells with the overall goal of inducing cells to form a functional vascular network ex vivo 
that will promote survival of the implanted tissue.  For instance, when skin-like tissues are 
constructed in vitro with endothelial cells along with fibroblasts and keratinocytes, there is more 
expedient integration with host vasculature than when endothelial cells are not included.35-36  
However, these skin-like constructs were less than 1mm thick and did not challenge oxygen and 
nutrient diffusion through the tissue (one of the primary limitations to tissue engineering 
vascularized constructs34).  A major limitation of prevascularization strategies is vessel 
phenotype heterogeneity, maturation and stabilization.34  It has been shown that immature 
vessels have a limited potential to integrate with host vasculature37 and are prone to regression.38  
Further, these vessels have been shown to be more fragile, leaky and can lead to the formation of 
edema after implantation.39  Additionally, the implantation of a foreign cell population invariably 
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leads to immunological responses leading to thrombosis and occlusion upon implantation.16  In 
contrast, an acellular, non-allogenic implant would allow for an off-the-shelf product which 
could prove invaluable for emergency situations such as burn and trauma wounds.  However, 
without some sort of vasculature or integrated delivery system, the most significant barrier to 
wound healing and three-dimensional regeneration is a lack of delivery of nutrients, oxygen and 
growth factors, beyond the limits of diffusion.4-5, 23  Prevascularization provides one means to 
solve this problem from the time of implantation.  However, prevascularization has been met 
with limited success due to retraction and inability to integrate with native vasculature.32, 34, 37-38, 
40 
The simplest way to promote invasion of host vasculature is to create channels similar in 
size to microvasculature and favorable for endothelial cell attachment.  One attempt has been by 
etching capillary patterns using microelectromechanical systems (MEMs) techniques into a 
silicon wafer, which served as a micromold for a poly(glycerol sebacate) scaffold.40  These 
scaffolds were bonded together, creating capillary networks that could be endothelialized under 
flow conditions in vitro.  Although in vitro results seem promising40, it is unclear how this 
system will behave in vivo, where ideal flow conditions are not met.  Another example of in vitro 
perfusion of microvascular tubes is seen when endothelial cells are seeded onto collagen gels 
molded around stainless steel needles.32  Although these tubes show normal microvascular 
functions including reactivity to cytokines, they showed a lack of basement membrane 
formation, which would likely be responsible for maintaining vessel integrity once implanted in 
vivo.  Finally, microchannels have also been created in a polyethylene glycol diacrylate 
(PEGDA) hydrogel41 and tested both in vitro and in vivo.  Although these microchannels resulted 
in host tissue infiltration within the actual channels of the implant and VEGF localization to the 
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host derived tissue, there was no evidence of host tissue infiltration into the hydrogel itself.41  
Hence, in order to promote endothelial cell recruitment in vivo, it has become a common strategy 
to combine angiogenic growth factor delivery with these scaffolds. 
4.3 CELL TRANSPLANTATION (CELL THERAPY) 
Cell therapy is also being explored as a treatment to promote angiogenesis.  Local injection of 
bone marrow derived progenitor cells have been used to replace the senescent fibroblasts and 
endothelial cells found in the ischemic wound.10  Also, bone marrow derived mononuclear cells 
containing the endothelial progenitor cell fraction implanted into ischemic limbs have been 
shown to promote collateral vessel formation with incorporation of endothelial progenitor cells 
into new capillaries.10  Some researchers are attempting to develop therapies that mimic the 
natural attraction of circulating endothelial progenitor cells, which have been shown to 
contribute to neovascularization in a hind-limb ischemia model in an immune-compromised 
mouse, improving perfusion and capillary density.54 
Administration of cells is a promising approach for therapeutic angiogenesis due to their 
ability to produce angiogenic cytokines and participate in vascular regeneration.117-119  One 
major obstacle is the retention of viable cells following transplantation.  Evidence indicates that 
the vast majority of transplanted cells neither survive for long after injection nor remain within 
the implanted location.120-122  Research shows that material-based deployment of cells using 
hydrogels improves efficacy, especially in the case of endothelial progenitor cells.123  Hydrogels 
are  attractive materials to serve as cell and drug carriers, as well as tissue matrices, due to their 
ability to absorb water and permeate solutes within the swollen matrices.124  Examples of natural 
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materials that have been explored for this purpose are collagen125, fibrin126, alginate127, gelatin128, 
and hyaluronan.124 
Bone marrow mononuclear cells and hematogenous stem cells are both capable of 
synthesizing and releasing VEGF and bFGF as well as other factors that induce endothelial cell 
proliferation.129-130  When bone marrow mononuclear cells were implanted in a canine abdominal 
aortic replacement model, endothelialization of an artificial blood vessel was observed.131  This 
cell type was also shown to increase collateral blood flow when injected in an ischemic 
myocardium rat model.132  The first clinical report using bone marrow mononuclear cells as 
angiogenic therapies describes increased ankle brachial pressure index, treadmill exercise 
tolerance and collateral blood flow without complications.59 
Embryonic stem cells are another cell source for cell-based angiogenic therapies.  Due to 
their pluripotency, embryonic stem cells have the ability to differentiate into any lineage, under 
the correct environmental conditions and cues.  For example, in the case of myocardial 
regeneration, conventional needle-based intramyocardial injections of embryonic stem cells may 
be less effective than the epicardial delivery of cellularized biomaterials, due to the cell-cell and 
cell-matrix interactions.133  A composite cell sheet made of cardiac progenitors derived from 
nonhuman primate ESC (for new cardiomyocytes) and adipose tissue-derived stromal cells (for 
trophic support) were used in a nonhuman primate model of myocardial infarction.133  These 
composites led to enhanced survival of implanted cells (compared to a sham), however, due to 
study limitations, they were only able to show improved cardiac function in small infarctions.133  
Recent clinical trials have explored the feasibility and safety of autologous stem cell therapy, 
specifically for peripheral artery occlusive disease.61, 134-136  The long-term results of these 
clinical studies remain undetermined and the potential for tumor formation is a concern.137-138 
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5.0  CONTROLLED GROWTH FACTOR DELIVERY 
Advances in the field of growth factor delivery for angiogenesis will greatly depend on our 
growing understanding of the mechanisms that regulate tissue level neovascularization.10  These 
mechanisms often involve the presentation of cytokines and growth factors, however, the manner 
in which they are presented are likely to be just as important as the molecule itself.  Specific to 
healing, the main growth factors involved include PDGF, FGF, VEGF, IGF, EGF and TGF-β.12  
These factors can be easily encapsulated, injected or incorporated, into a scaffold and delivered 
in combination with each other as well as other factors.9, 12, 67, 139-140  Unfortunately, delivery and 
administration of growth factors currently lacks the sophistication required to orchestrate a stage-
wise series of events. 
At present, growth factors are commonly applied in solution form via bolus injection.1  
This method of delivery is high in cost and often results in negative side effects at non-target 
sites, such as promotion of disease.99, 101  Additionally, due to short half lives of growth factors, 
following hydrolysis by enzymes (bFGF half life = 3-10 minutes141, VEGF half life < 30 
minutes142) the bioavailability of the bolus injection is often low.  Taken together, bolus 
injections of growth factors can result in non-functional tissue, which translate to leaky blood 
vessels in the case of angiogenesis.1  Sometimes, a high concentration of growth factor that 
compensates for the loss of bioavailability leads to toxicity at the site of injection.25  In order to 
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be an effective therapy, a growth factor has to reach the site of injury without degradation and 
remain at the target site long enough to exert its action.25 
In the case of peripheral vascular disease, which affects 15% of the adult population143, 
obstruction of the blood supply reduces blood flow to the upper and lower limbs.  It is believed 
that therapies that enhance angiogenesis can improve blood flow and relieve symptoms.144  
Although bolus injection of VEGF showed promising results in animal peripheral vascular 
disease studies145-147, no significant improvement was observed in phase II clinical trials.148-149 
There is increasing evidence that enabling growth factors to exert their biological 
function efficiently requires the design and development of release technologies that provide 
controlled delivery, while preventing unwanted side effects.25  Controlled release polymer 
systems and liposomes have shown to improve protein safety and efficacy.150  Encapsulation of a 
growth factor in a delivery system (or attaching a growth factor to a polymer carrier) has been 
demonstrated to hold a great deal of promise for growth factor based therapies.25  This method of 
protecting a protein allows delivery of unaltered proteins and is useful for chronic administration, 
leading to treatments for a number of diseases.150-151  This strategy has found widespread use in 
wound healing and tissue regeneration, allowing for improved bioavailability, reduced frequency 
of administration, minimized release to non-target sites and more effective routes of 
administration.  Carriers and delivery systems act as depots or reservoirs for high concentrations 
of growth factors while providing a protective environment.  Delivery of specific cues to the 
proper site may allow for the regulation of the phenotype of host cells and thus guide tissue 
formation, healing or regeneration.25  Sometimes, the carrier or delivery systems can also serve 
as an artificial extracellular matrix for cellular migration, while maintaining space in which 
tissue regeneration can occur.25  An ideal delivery system should: 1) consist of a non-cytotoxic 
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and biodegradable carrier material, 2) have a feasible preparation method that does not affect 
protein activity, 3) retain a high loading efficiency and a controlled release profile, 4) target and 
be retained at the desired site of action, and 5) restrict the protein conformational mobility and 
protect the protein from physical and chemical degradation.25  A broad range of biomaterial-
based delivery technologies are being discovered and have the ability to control release kinetics 
of varying biological cues for diverse biomedical applications.  There is great potential for 
applications in immunology, oncology and tissue engineering, where sustained growth factor 
release from a scaffold would be desired.151  
Poly(lactide-co-glycolide), or PLG, is an attractive choice for controlled delivery of 
growth factors, as it degrades by hydrolysis to lactic and glycolic acid and has been used for over 
thirty years in a variety of medical devices.  Microspheres can be readily made using a double 
emulsion technique, a process that can easily incorporate growth factors, where growth factor 
delivery is coupled to the degradation of the polymer.152  Over the years, other polymers and 
delivery systems (including microspheres) have also been explored for growth factor delivery, 
specifically with angiogenic growth factors. 
5.1 PROOF OF CONCEPT MODELS 
As proof of concept of local growth factor administration, bFGF was loaded into resin-based 
microspheres in a non-disease model, where microspheres were injected directly into the 
coronary artery.153  Local delivery of bFGF, specifically to the heart and no other organs, was 
shown when compared to non-loaded microspheres, resulting in an increase in proliferating 
cells.153  Basic FGF has also been loaded into heparin immobilized PLG microspheres and 
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injected into the subcutaneous space on the dorsal side of a mouse.154  After one week, the skin 
surrounding the areas of bFGF-loaded microspheres showed an increase in capillary density, a 
response which was enhanced by heparin immobilization.154  In addition, when VEGF was 
loaded into PLG microspheres for release over 21 days in a rat corneal implant model, an 
increase in angiogenic area was seen as a dose-dependent response to the amount of VEGF 
loaded.155 
5.2 HINDLIMB ISCHEMIA MODELS 
Localized delivery of angiogenic growth factors that overcome the limitations of bolus injections 
has led to the exploration of angiogenic growth factor delivery in a number of disease models.  In 
the case of a mouse ischemic hindlimb model, controlled release of VEGF from a poly (lactide-
co-glycolide) scaffold for 28 days was able to improve tissue perfusion, capillary density and 
incidence of mature vessels compared to a blank scaffold or no treatment at all.144  In another 
mouse ischemic limb model, VEGF loaded PLG nanoparticles were injected into the ischemic 
thigh adductor muscles, and VEGF was released over a 4 day period.156  When compared to 
untreated ischemic limbs, VEGF nanoparticle treated limbs showed a significant increase in 
blood vessel volume.156  In a similar study, where VEGF is released from a PLG scaffold over a 
longer period of time, PLG-VEGF scaffolds resulted in improved tissue perfusion, greater 
capillary density and more mature vasculature, compared to the controls over a 28 day period.144  
Alternatively, the release of bFGF was explored in similar models.  Ionic gelatin-based 
hydrogels have been shown to release bFGF for 28 days.157  When these bFGF-releasing 
hydrogels were applied to the quadriceps in a mouse hindlimb ischemia model, reperfusion was 
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significantly higher than a bolus injection of bFGF.157  In a rat ischemic hindlimb model, a 
fibrin-based scaffold, loaded with heparin, VEGF and bFGF, was implanted between the 
superficial abductor and semi-membranous membrane.158  After 14 days, a statistical increase 
was observed in perfusion of the limb and capillary number when compared to a blank 
scaffold.158 
Lastly, an injectable hydrogel has been proposed as a feasible option for VEGF delivery, 
due to its ability to be injected in a minimally invasive procedure.159  Specific attention has been 
given to alginate, a naturally occurring polysaccharide, given its biocompatibility and 
availability.160-161  In a mouse ischemic limb study, an injectable biodegradable alginate 
hydrogel, allowing sustained and localized release of VEGF, demonstrated release at a desirable 
concentration for extended periods of time and significant improvement in blood vessel density 
and restored blood flow when compared to bolus injection or hydrogel alone.143 
5.3 MYOCARDIAL INFARCTION MODELS 
Left coronary artery ligation has been employed as a model for myocardial infarction, allowing 
for post-infarction treatment studies.162  A chitosan hydrogel has been employed as a growth 
factor delivery vehicle in a rabbit myocardial infarction model.162  In this model, the hydrogel is 
UV-crosslinked after it is applied to the infarct site.162  Left ventricle systolic pressure as well as 
endothelial cell presence was statistically higher in bFGF loaded hydrogel when compared to the 
blank hydrogel or no treatment at all.162  A gelatin hydrogel microsphere system has also been 
shown to release bFGF in a myocardial infarct model.163  Four weeks following coronary artery 
ligation in rats, infarcts treated with bFGF loaded microspheres were shown to increase 
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myocardial blood flow as a result of myocardial angiogenesis, as well as improve the left 
ventricular systolic and diastolic function.163  Another gelatin hydrogel microsphere system was 
explored where bFGF-loaded microspheres were injected in a myocardial infarct model and 
observed in dogs for 17 days.164  These microspheres were able to improve left ventricle function 
as well as microvessel density, when compared to a saline injection.164 
5.4 ANIMAL MODEL TRANSLATION 
Although much success has been seen in the animal models mentioned above, very few of these 
therapies show promising results in clinical trials.  One explanation for this is that the animals 
used in these models enter the study as healthy individuals.  Many patients, especially peripheral 
artery and myocardial infarction patients, have other associated medical conditions that can 
contribute to their response to certain therapies.  Also, in some cases, such as a myocardial 
infarction model, application of the therapeutic treatment immediately following the medical 
condition is not clinically possible.164  Lastly, these strategies are being explored in animal 
models, which will behave differently than they will in humans.  Alternatively, the treatments 
explored in these models do not account for the stage-wise characteristics of the angiogenesis 
cascade. 
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6.0  STAGE-WISE ANGIOGENESIS 
Angiogenesis occurs through a series of distinct steps, vessel destabilization, endothelial cell 
proliferation, endothelial cell migration and finally culminates is vessel maturation.9  This 
process is often referred to as stage-wise angiogenesis or the angiogenesis cascade.165-170  Each 
step along the way requires the presence (and sometimes absence) of different factors.64  
6.1 EARLY ANGIOGENESIS 
Vessel destabilization is the natural response to stimulus such as injury, inflammation, hypoxia 
and neoplastic transformation,10 which are all scenarios in which blood vessel growth is needed.  
Soluble growth factors, cytokines and both cell-cell and cell-matrix interactions, all play a role in 
activating endothelial cells to begin angiogenesis.10  Once activated, endothelial cells attract 
leukocytes and blood platelets that release a multitude of pro- and anti-angiogenic factors.9  
Endothelial cells begin to loosen their contacts with each other, as well as the supporting 
basement membrane and pericytes, leading to increased vascular permeability and deposition of 
fibrin.9, 65  Degradation of the basement membrane of an existing vessel, controlled by enzymes  
expressed at the tips of the capillaries (urokinase plasminogen and matrix metalloproteinases), 
must occur to allow for formation and advancement of a capillary sprout.8, 10  Angiogenic growth 
factors involved in initiation of angiogenesis include VEGF and TGF-β, allowing the local 
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resident endothelial cells to invade and migrate through the ECM, proliferate and form new 
immature tubules.10 
Activated endothelial cells migrate on the fibrin scaffold (provided by fibroblasts) and 
invade towards the angiogenic stimulus, contributing to the next phase of proliferation and 
migration.9-10  Fibroblasts are a rich source of angiogenic cytokines, which are responsible for 
angiogenic stimulus.  These cytokines have been shown to induce endothelial cells to form 
capillary-like networks in vitro, an action that cannot be completely inhibited by VEGF 
antibodies.10  As endothelial cells receive signals to proliferate, they form an immature capillary 
lumen.9-10  Migrating endothelial cells follow a cytokine gradient and rely on adhesion molecules 
and integrins (especially alpha-v/beta-3) to mediate their cell-matrix interactions.10  Migration is 
assisted by the degradation of the extracellular matrix, which in turn is driven by matrix 
metalloproteinases (MMPs).  Each MMP exists for a specific extracellular matrix protein.  MMP 
gene transcription is induced by growth factors and cytokines, released as proenzymes and 
cleaved by proteinases.10  As endothelial cells migrate into the area of neovascularization, they 
further proliferate, forming cytoplasmic vacuoles, which later become immature, leaky tubules.10 
6.2 LATE ANGIOGENESIS 
The final step of angiogenesis is the maturation of the new vessel via the recruitment of smooth 
muscle cells and pericytes that cover the vessel and stabilize it, allowing blood to flow without 
leaking.8  Endothelial cell proliferation and migration are inhibited and new basement membrane 
is secreted.9  Simultaneously, endothelial cells re-form their contacts with each other as well was 
the basement membrane proteins.9  Pericytes are recruited to an immature vessel by PDGF and 
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S1P, where they can differentiate into mural cells.9, 65  Factors that are present at this stage of 
angiogenesis inhibit endothelial cell proliferation, but still provide signals to promote survival of 
endothelial cells to endothelial cells.65  In wound angiogenesis, when normoxia is restored and 
inflammation subsides, the levels of growth factors that promote angiogenesis decline.171 
6.3 PHYSIOLOGIC GROWTH FACTOR TIMING 
Angiogenesis is stimulated early in the wound healing process, with VEGF acting as one of the 
main initiators.172  A summary of individual factor involvement can be seen in Figure 2, 
reproduced from Fischbach, et al.1  While much is known about the “wound healing cascade” or 
the profile of growth factors involved at various stages of wound healing, researchers are just 
beginning to learn about the “angiogenesis cascade”, where not only is there a time-dependent 
growth factor concentration profile, but also the expression of their receptors.25  Following 
wound induction in an animal model, VEGF upregulation has been shown to occur as early as 
three days and last up to seven days.173  An even more immediate response is seen with the 
upregulation of bFGF because bFGF is released immediately from the extracellular matrix of 
damaged tissue.174  Additionally, it has been shown that in following hernia repair in humans, 
both VEGF and bFGF are upregulated over the first 4 days post-surgery, where bFGF already 
shows decreasing values by day 4.175  Thrombin, the clot that forms during the first hour of the 
wound healing cascade, has been shown to upregulate the expression of the VEGF receptor, 
enhancing the effects of VEGF.176 
With respect to the later stage of angiogenesis, binding of Ang-1 to the Tie2 receptor on 
endothelial cells has been shown to upregulate PDGF production by endothelial cells.177-178  It 
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has been shown that an absence of PDGF during this stage leads to poorly-formed and immature 
blood vessels.179  Additionally, when VEGF is present for long periods of time, the result is 
small, over-branched, leaky vessels, similar to those of tumor vessels.173  It has also been found 
that diabetic patients with chronic non-healing ulcers have high levels of circulating VEGF and 
low levels of PDGF.19, 180  At the end of angiogenesis, growth factor levels decrease, and 
vascular pericytes secrete TGF-β, which acts to inhibit vascular proliferation.181 
 
 
 
Figure 2.  Growth factor involvement in angiogenesis events.1 
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6.4 GROWTH FACTOR INTERACTIONS 
Given the limited success of delivering only one angiogenic factor, as well as the multitude of 
factors that are involved with various stages of angiogenesis, some investigators have 
hypothesized that a combination of angiogenic growth factors might be the key to inducing 
functional angiogenesis that integrates with native vasculature.9, 67, 139-140  However, some 
combinations of factors has shown to inhibit certain steps of angiogenesis, while other 
combinations of factors have shown to inhibit each other.  For example, it has been shown that 
PDGF inhibits the angiogenic effects of bFGF, when the two factors were presented to bovine 
aortic endothelial cells.71  Similarly, S1P inhibits the task of human umbilical vein endothelial 
cell recruitment182, a task thought to be performed by VEGF.9  It is also known that VEGF 
upregulates S1P receptors on endothelial cells,183 indicating that it would be necessary to present 
VEGF before S1P for the purpose of growing new blood vessels.  The evidence that dual 
delivery of growth factors does not solve the problem of generating functional, integrated 
vasculature in vivo, suggests that angiogenic growth factors should be presented in profile in 
which they are presented during native angiogenesis. 
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7.0  SEQUENTIAL DELIVERY 
7.1 INTRODUCTION 
Decades of research have revealed that surface-bound and secreted biomolecules displayed and 
exchanged by cells form an organized “message” that can be accentuated or even inverted 
depending upon the temporo-spatial organization of the stimuli.  It is becoming apparent that 
combinations of these various biomolecules can form organized sets of “instructions” that can be 
accentuated or even inverted depending upon the temporo-spatial organization of the stimuli (e.g. 
see examples from adaptive immunity184, immunological tolerance185, pancreatic insulin 
regulation186, lipolysis187, and osteocoupling188 as just a few emerging examples).  The complex 
processes of cell migration, differentiation and proliferation are typically dependent on both the 
presence/absence of specific growth factors and their time-dependence.98  Growth factor 
signaling plays a significant role in the sequence of events responsible for both the development 
and regeneration of tissues, where the timing and order of presentation is crucial to the 
downstream signaling events.1  Consequently, it is not surprising that the complexity of these 
biological processes dwarfs the complexity of current treatments intending to direct, accelerate 
or repair them.  A prominent example of a biological process that is currently over-simplified by 
existing treatments is angiogenesis (the growth of neovasculature from existing vasculature).  
VEGF, FGF and angiopoietin-2, are required to disrupt the structure of preexisting blood vessels 
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and to promote the proliferation and migration of new cells to form new immature vessels.  
Angiopoietin-1 and PDGF are required to stabilize these newly formed blood vessels.189-191  
Another example where specific release kinetics would be desired is the release of gonadotropin 
releasing hormone, where a pulsatile release profile is desirable.192  Sustained release of this 
hormone does not result in increased fertility.  Polymer systems capable of distinct release 
kinetics for growth factors may be critical to control biological processes. 
It is thought that mimicking the natural sequence of “instructions”, as opposed to 
providing multiple “instructions” simultaneously, is the key to successful therapeutic 
angiogenesis.9  An appropriate system for delivery would not only exert control over the 
presence over factors but the absence as well, with the overall goal of mimicking physiological 
signaling and achieving biological functionality.1  Creating an environment that mimics the 
multifactorial cascade of events that naturally occur in the body to accelerate or exploit the 
inherit capability of tissue growth is one goal of the regenerative medicine field.  This process 
requires recapitulation of at least several of the spatial and temporal microenvironments 
presented naturally in the healing process.  A number of approaches have been explored to 
achieve site specific and time-controlled delivery of therapeutics.  However, many of these 
current approaches still have limited clinical utility, due to the challenging requirements for the 
delivery of multiple therapeutic agents in the proper time frame required for many biological 
events.193 
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7.2 COMBINED RELEASE SYSTEMS 
Only recently has delivery technology developed to the point where engineers are capable of 
varying the rate of multiple biological “instructions” with respect to one another.194-196  One 
method to control the delivery of growth factors in a way that can approximate the way in which 
they are presented naturally is to combine multiple release systems (gels, polymer microparticles, 
scaffolds, etc.) with two different release profiles, so that the growth factors are released at two 
different rates.67, 139-140  For example, one factor can be pre-encapsulated in polymeric 
microspheres and then mixed into a polymer scaffold during the fabrication process.67  Proteins 
are most easily encapsulated using a double emulsion procedure that utilizes an internal aqueous 
(protein solution) phase during processing.  The double emulsion process of microsphere 
fabrication begins with a protein solution being added to and heavily mixed with a polymer 
solution, where the solvents are immiscible, forming the first emulsion.  This emulsion is poured 
into the immiscible solvent of the polymer solution and stirred, forming the second emulsion.  
The resulting double emulsion is poured into a polyvinyl alcohol solution, where the polymer 
solvent evaporates, leaving behind solid microparticles with encapsulated protein.197 
Polymer scaffolds can be fabricated by a variety of processes.  One of these processes is 
solvent-casting particle-leaching in which salt particles are added to a polymer solution of 
specific diameter to produce a uniform suspension.198-199  As the solvent evaporates, the polymer 
matrix is left behind with salt particle embedded throughout.199  When this matrix is immersed in 
water, the salt leaches out, producing a porous structure.  Another method for scaffold 
fabrication involves gas foaming, where a biodegradable polymer is saturated with carbon 
dioxide at high pressures.200  As pressure is returned to atmospheric levels, the solubility of the 
gas in the polymer decreases, resulting in nucleation and growth of gas bubbles in the 
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polymer.199  A third method of scaffold fabrication involves non-woven scaffolds have been 
produced from polyglycolic acid and polylactic acid,201 which led to the development of a fiber 
bonding technique, where the resulting scaffold has increased mechanical properties.202  
Additional  methods of scaffold fabrication include, but are not limited to: phase separation203, 
melt molding204, freeze drying205-211 and solution casting212.  All of these methods allow for the 
incorporation of polymer microspheres, resulting in a combination of two release systems. 
Theoretically each polymeric system allows (individually) for tuning of spatial and 
temporal delivery of growth factors (discussed in Chapter 5.0 ), allowing for spatially and 
temporally controlled delivery of growth factors.1  In the method discussed here, the factor that is 
expected to act early is incorporated into a rapidly releasing phase, and the growth factor 
expected to act later in the process is incorporated into a phase with more sustained release.   
Even though both factors are released simultaneously, if the rates of release are different enough 
to capture the distinctions between the various stages in the healing cascade (amounts, time-
frames of biological events), it should serve the healing process to a greater degree than 
administration of both factors at the same rate. 
An example that employs this technique, and the first attempt of dual angiogenic growth 
factor delivery through a polymeric system, is adding polylactic co-glycolic acid microspheres 
that have been loaded with PDGF to a VEGF loaded scaffold and implanting into the 
subcutaneous pocket of a rat.67  In this example, VEGF largely associates with the surface of the 
scaffold, allowing for rapid release, but PDGF is more evenly distributed through the scaffold.  
The scaffold as a whole results in temporal release of VEGF and PDGF (Figure 3).67  When 
compared to bolus injections of the same factors individually, a statistical significantly difference 
in vessel density was observed at four weeks.67 
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In a similar technique, PDGF was encapsulated in polylactic co-glycolic acid 
microspheres and mixed into a VEGF-containing alginate gel in a layered fashion, resulting in 
VEGF and PDGF release at different rates from one layer and VEGF release alone from the 
second layer (Figure 4).213  These layered scaffolds were implanted into mice in a hindlimb 
ischemia model.  Although the PDGF and VEGF layer scaffold was able to induce angiogenesis 
to great extent than a blank scaffold, as well as show varying degrees of angiogenesis in the two 
layers, the layer with both PDGF and VEGF did not induce angiogenesis to a great degree than 
PDGF alone.  Additionally, it is shown that when VEGF is present without PDGF, there is an 
increased blood vessel density. 
 
 
 
 
Figure 3.  Cumulative release of VEGF and PDGF from a combined polymeric scaffold.67 
In vitro release kinetics.  (A) In vitro release kinetics of VEGF from scaffolds fabricated from 
PLG (85:15, lactide:glycolide), measured using 125I-labeled tracers. (B) In vitro release kinetics 
of PDGF pre-encapsulated in PLG microspheres (triangle - 75:25; box - 75:25), before scaffold 
fabrication.  Data represent the mean (n = 5), and error bars represent standard deviation (error 
bars not visible are smaller than the symbol). 
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A third example of VEGF and PDGF delivery that has been explored is the combination 
of low molecular weight and high molecular weight alginate hydrogel for release of VEGF and 
PDGF at different rates, where VEGF release is quicker at first, followed by an increase in 
release of PDGF (Figure 5).214  This gel was injected into rats following left anterior descending 
coronary artery ligation in a myocardial infarction model.  While an increase in alpha smooth 
muscle positive vessels were observed when both VEGF and PDGF were delivered, there was no 
statistical difference in vessel density or left ventricular function when the VEGF and PDGF 
group was compared to delivery of PDGF alone. 
Sequential delivery of growth factors has also been approached using the development of 
a composite system consisting of gelatin microspheres that have been incorporated into a 
synthetic hydrogel matrix.215  This system was designed to release IGF-1 and TGF-β for the 
purpose of articular cartilage healing, using a non-invasive injectable therapy.215  In this study, 
factors such as crosslinking extent and polymer density, were used to control the rate of release 
of each factor.215 
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Figure 4.  Total release of VEGF and PDGF from a layered polymeric scaffold.213 
VEGF (a) and PDGF (b) release from layered scaffolds was determined using radiolabeled 
growth factor (n = 4). The overall release profile of VEGF (a) is similar in layer 1 (cross) and 
layer 2 (circle) with an initial burst of VEGF followed by a steady release.  Pre-encapsulation of 
PDGF in PLG microspheres slowed its release from layer 1 of scaffolds (b).  The quantity of 
VEGF and PDGF released was proportional to the total mass of growth factor incorporated in 
each layer (1.5 mg VEGF and/or 3 mg PDGF in layer 1; 3 mg VEGF in layer 2). Values 
represent mean and standard deviation. 
 
 49 
 
 
Figure 5.  VEGF165 and PDGF-BB release from alginate hydrogels of varying molecular 
weight.214 
The cumulative release of VEGF-A165 and PDGF-BB from alginate hydrogels in vitro following 
incubation in PBS at 37 °C. Values are given as mean ±SEM, n=4 at each data point. 
 
 
Additionally, alginate and poly lactide-co-glycolide were combined to create a release 
system, capable of releasing VEGF and PDGF.216  This system is capable of delivery of multiple 
angiogenic factors with distinct kinetics (Figure 6).216  Release kinetics were confirmed in vivo in 
a mouse hindlimb ischemia model, where PDGF release was detected until 42 days, but VEGF 
content was only detected until 28 days.216  In this model, sequential delivery of VEGF followed 
by PDGF resulted in the formation of mature (alpha smooth muscle actin positive) vessel 
formation. 
Systems in which release systems are combined for the temporal delivery of growth 
factors will need to be optimized for each particular treatment, formulation, growth factor and 
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delivery strategy, in order to be effective.  Optimization would include identification of key 
growth factors, the mode of factor delivery, method of system fabrication and desired release 
kinetics for each particular tissue injury or disease.216  Additionally, when combining two release 
systems, the resulting release profile is often constant release of both factors, simply at different 
rates.  This may not be optimal for processes that, if occurring simultaneously, may conflict with 
one another.  In this case, it might be beneficial to temporally separate the signals that promote 
each individual processes, as discussed in Chapter 6.0.  In these cases, the release of one or more 
of the factors would need to be delayed for a predetermined amount of time (according to what 
happens physiologically), while an initial factor is released.  These systems require further 
investigation before reaching the point where delayed release is a possibility. 
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Figure 6.  In vitro release kinetics of pre-encapsulated PDGF and VEGF from alginate 
fabricated from poly lactide-co-glycolide.216  
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7.3 LAYER BY LAYER FILMS 
One strategy that attempts to overcome the hurdle of factor release overlap is the use of stratified 
systems such as layer-by-layer (LBL) films.  LBL films consist of electrostatic layer-by-layer 
assembly with a cationic polyelectrolyte and anionic particles such as protein molecules.217  The 
fabrication process entails sequential adsorption on monolayers of oppositely charged polymers, 
colloids or other materials onto a solid substrate to form a cohesive, ionically crosslinked thin 
film, with the idea that films will surface-erode in a fashion that releases factors in the opposite 
order to which they are loaded into the stratified system.218  This technique takes advantage of 
the attractive electrostatic forces between charged polymers and oppositely charges surfaces (See 
Figure 7).219  Multilayers can be deposited rapidly and inexpensively atop large area surfaces of 
any geometry while allowing for nanometer-scale control over a range of physical properties.218 
 
 
Figure 7.  Layer-by-layer film fabrication technique.219 
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Polyelectrolyte multilayers have attracted much interest for their versatility, ease of 
preparation and ability to coat virtually any substrate (titanium, ceramic, polymer, glass).220-221  
This assembly technique allows for absolute control over the order in which multiple functional 
elements are incorporated into a growing film.  Because an LBL film is an erodible multilayer 
that deconstructs in aqueous conditions via disassembly and/or breakdown of the constituent 
polymers, it is being explored as a potential controlled release delivery system.221  By employing 
degradable polyelectrolytes as building blocks, the ability to tune the degradation kinetics of 
multilayer assemblies has been demonstrated and used to control the release kinetics of 
compounds embedded in these films (examples: antimicrobial, anti-inflammatory, drug-releasing 
stents),221 while allowing for the incorporation of sensitive biomolecules (proteins) and DNA 
(due to mild aqueous conditions during fabrication).218  Hydrolytically degradable LBL thin 
films can be constructed from any molecular species that is either intrinsically charged or that 
can be encapsulated in a charged “carrier”.222  A main feature of this technique is its ability to 
small features, nonplanar surfaces and microparticles, while still being able to build complex 
special architectures.222-224  
Early drug release experiments with LBL films using hydrogen bonded-based 
interactions showed films that fall apart rapidly at near neutral pH, resulting in instantaneous 
method of drug release.220  A second approach was to pre-construct LBL films from inert 
polymers with drug loaded into the permeable network for diffusive or pH induced release, 
allowing for sustained release of small molecules.225  However, in this approach, large molecules 
such as proteins remained trapped.  A hydrophobic, and thus slowly degrading, poly(β-
aminoester) has been used as a cationic polymer, with either heparin sulfate or chondroitin 
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sulfate as an polyanion, for LBL film fabrication, allowing for release of a growth factor (large 
protein) without rapid degradation of the film.220  These films demonstrated sustained controlled 
release of bFGF (over 12 days) from a synthetic, biodegradable polymer LBL drug delivery 
system, where release is tunable through the polycation, polyanion and number of layers used to 
construct the film.220  Basic FGF released from the film exhibits enhanced ability to promote 
proliferation in pre-osteoblast cells compared with exogenous supplementation.220  Another 
example of the use of the cationic poly(β-aninoester) for the fabrication of LBL films is 
demonstrated in a transcutaneous drug delivery model, using a model protein.221  In this model, 
researchers have demonstrated that protein antigen released from multilayer patches can be 
acquired by immune cells in the skin within hours of application of the film.221  Additionally, 
they show that two molecules (antigen and adjuvant) can be loaded together and released with 
distinct kinetics, as may be desirable for temporally controlling the induction of a therapeutic 
response.221 
One example of LBL films being used in an animal disease model is the delivery of 
gentamicin to a rabbit bone infection model, using titanium implants.226  Typical treatment of 
infection following orthopedic surgery is a two stage surgical procedure and several weeks of 
intravenous antibiotics.227  In this study, thin films with antibiotic functionality were constructed 
using the LBL technique by alternating the deposition of a hydrolytically degradable poly(β-
amino ester), biocompatible poly(acrylic acid), and the therapeutic gentamicin.226  With a burst 
release followed by zero-order sustained release for over a week, the films fabricated in this 
study demonstrate the release of one molecule by two release mechanisms, combining to match a 
desired release profile. 226    In this study, implants significantly decreased the viable bacteria 
count compared to the uncoated implant, allowing for a one-stage re-implantation procedure 
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after an infected arthroplasty .226  In another example, when heparin was loaded into a 
degradable LBL film, distinct non-linear release that can be predicted within 10% at various pH 
conditions was observed.222  It is believed that the distinct release regimes observed correspond 
with the degradation of individual layers of the film.222  A technique similar to the ones 
described here could be utilized for the delivery of two different factors as well.  These results 
are an important step forward in the effort to develop complex release architectures where a 
specific release profile is desired. 
The techniques employed in the previously mentioned studies can be applied not only to 
the precise control over delivery of one protein, but the combined, temporal or sequential, 
delivery of two or more molecules.  A system made from LBL poly(L-glutamic acid) (PLGA) 
and poly(L-lysine) (PLL) films into which cationic CD [pyridylamino-β-cyclodextrin (pCD)] and 
DNA have been embedded was employed for the delivery of two different DNA plasmids.228  
Expression of both genes was tracked over an eight hour period on attached COS cells.   SPT7 
expression was detected as early as two hours following exposure, while expression of EGFP 
was not observed until four hours after exposure (Figure 8).228  When the placement of the 
plasmids in the thin film was reversed, so was the timing of expression.228 
A multi-agent LBL film, capable both charged macromolecule and uncharged small 
hydrophobic drug delivery was developed, where release was controlled by the hydrolytic 
degradation of a poly(β-amino ester).193  The intrinsic properties of the multilayer, the drug 
components and the layering agents in the film, all contribute to the release profiles of each 
component.193  Release of heparin occurred over a 50 hour period, where 50% release occurred 
at 6 hours, while release of dextran sulfate occurred over a 120 hour period, where 50% release 
occurred at 37 hours (Figure 9).193  These results demonstrate distinct release profiles of two 
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different molecules from the same biomaterial, where release profiles were largely controlled by 
the selection of layering agent.193 
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Figure 8.  COS expression of temporal delivery of DNA.228 
Expression of SPT7 and EGFP in COS cells grown on the surface of multilayered films (A and 
B) for 2 h (C and D), 4 h (E and F) and 8 h (G and H).  The expression of SPT7 (red) and GFP 
(green) was detected with antibodies (A, C, E, and G).  Nuclei were visualized by Hoechst 33258 
staining (B, D, F, and H). 
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Figure 9.  Release of heparin and dextran sulfate from LBL film.193 
Release profiles of radiolabeled anionic polysaccharide and film thickness changes for (top) the 
HEP film and (bottom) the DS film. 
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When considering the ability to finely tune release from an LBL, it is necessary to 
consider interlayer mixing, as this will have a negative effect on the ability to sequentially 
release factors.  Current research involves adding physical barrier layers between layers to 
control interlayer diffusion following hydration.218  Successfully achieving sequential delivery in 
these systems will require a balance of adding enough layers to decrease intermixing, while 
minimizing scaffold thickness, as to avoid bulk (internal, heterogeneous) erosion throughout the 
polymer layers.  Another approach to decrease interlayer mixing and diffusion is covalently 
crosslinked barriers (instead of ionically crosslinked barriers) that lead to compartmentalized 
structures.218  LBL films are also limited by the inability to control the relative positions and 
distributions of multiple species residing within a single film, resulting in highly disorganized 
architectures.218  Over the years, many modifications have been developed, including the use of 
colloidal particles, where the colloidal core is destructed, leading to hollow particles.  
Additionally, the use of porous templates such as anodic alumina pores leads to tubular objects 
and sacrificial substrates, and eventually self-standing films.229 
Results from the fabrication of LBL films are an important step forward in the effort to 
develop complex release architectures that combine more than one release agent for optimized, 
multi-drug release.  LBL films can be applied to the surface of many implant materials, such as 
titanium orthopedic implants or cardiovascular stents.  In many biomaterial implants, the need 
for sequential delivery of more than one agent would be desirable.  LBL films is an emerging 
and developing area of research and can benefit from the interdisciplinary work of researchers in 
biology, medicine and the pharmaceutical sciences.219 
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7.4 MICROCHIP TECHNOLOGY 
In situations where precise control over drug release is imperative, due to a small therapeutic 
window for therapeutic concentration, or a therapeutic concentration that changes with time, 
microfabrication techniques may be ideal.230   The microprocessing techniques employed for 
drug releasing microchips are the same techniques used to make microprocessors for computers 
and other microelectric devices.  Some examples of these are micropumps or microvalves, 
however, these both have limits on reliability and the types of solutions that can be used.231  The 
first demonstration of a microchip used for drug delivery was developed in 1999, where solid-
state silicon microchip reservoirs were loaded with sodium fluorescein and released in a pulsatile 
manner over several days (Figure 10).232  Each reservoir is covered on one end by a thin gold 
membrane that serves as an anode in an electrochemical reaction.230  The reservoirs can be filled 
with any combination of drug or drug mixtures in the solid, liquid or gel state, by inkjet printing 
or microinjection.230  When release is desired, a voltage is applied between the anode membrane 
and a cathode, causing the anode to dissolve and the drug to be released from the reservoir.230  It 
was demonstrated that release from each reservoir could be controlled individually, creating a 
possibility for achieving many complex release patterns.232 
A resorbable polymeric microchip was created from poly(L-lactic acid) (PLA), chosen 
for its slow degradation, allowing for complete release before degradation of the microchip, as 
well as its biocompatibility.223, 233-235  PLA microchips were fabricated with 36 reservoirs, each 
with a volume of 120-130nL.223  When four reservoirs were loaded with either heparin or 
dextran, release of each molecule was distinct (Figure 11).223 
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Figure 10.  Pulsatile release of a single substance from a microchip device.232 
The total mass of sodium fluorescein released into PBS over a period of several days is shown 
for each of four reservoirs.  This release study was conducted in PBS stirred with a magnetic 
stirring bar at room temperature.  The device was submerged in the PBS for >36 h before the 
first release to ensure that there was no leakage from any of the loaded reservoirs. 
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Figure 11.  Cumulative percent of initial loading released from microchip device in vitro.223 
Release results are shown for a representative device that was loaded with both 14C-dextran 
(crosses) and 3H-heparin (circles). 
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An in vivo study was carried out using a fully implantable silicon microchip, containing 
24 reservoirs that were filled with mannitol.236  These microchips were placed into a stainless 
steel housing and implanted in the dorsal subcutaneous space of rats.236  Mannitol release was 
measured from urine samples, demonstrating that reservoirs successfully release on average 85% 
of its contents on demand (Figure 12).236 
 
 
 
Figure 12.  In vivo release profiles (urine measurements) of mannitol release from a silicon 
microchip.236 
 
 
Advantages of this technique include its versatility, small size, quick response times and 
lower power consumption232, where release is controlled by the size and polymer of the device, 
number and volume of reservoirs and thickness and material of the membrane.223  However, in 
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some instances, the small volume of the reservoir becomes a limitation of the device.237  
Potential applications for devices such as these include implantable devices with patterned 
delivery of multiple drugs or an oral delivery device.223 
7.5 EMERGING RELEASE TECHNOLOGY – TUNABLE MICROPARTICLES 
The ability to precisely program a release profile into a degradable microparticle delivery system 
(such as the ones described in Section 7.2), through manipulation of physical properties and 
fabrication conditions, could lead to flexible and injectable sequential delivery systems.  In most 
hydrolytically labile polymer release systems, the release of large encapsulated agents (proteins, 
nucleic acids) is dictated primarily by the degradation and erosion of the polymer.196, 238  If a 
clear correlation between release of an agent and degradation/erosion of a delivery system can be 
derived, it may be possible to dictate the release profile of the agent.  For instance, one method 
for controlling release kinetics is PEG-based surface modification of porous silicon 
microparticles.239  Incorporation of high molecular weight PEG into the backbone of the polymer 
was able to delay degradation of the silicon microparticles.239  Although controlling release by 
chemical modification is a viable way to influence release behavior, this strategies may be 
limited to circumstances where polymer structure is of little importance to the desired 
formulation. 
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Figure 13.  Degradation kinetics of large pore and small pore silicon particles.239 
Degradation kinetics of large pores (30–50 nm) and small pores (10 nm) silicon microparticles as 
evaluated by inductively coupled plasma atomic emission spectrometer. The degradation kinetic 
profile is expressed as a percentage of the total silicon contents released to the degradation 
medium. 
 
 
A more comprehensive understanding of how release is dictated by the processes 
occurring in degrading release systems would permit both flexibility and precision while tuning 
release of biological agents.195-196  It is widely known that bulk eroding polymer matrices can 
range from linear release, to four-phase release: initial burst, lag phase, secondary burst, terminal 
release.195  The degradation mechanism of the polymer, matrix crystallinity and physical 
properties of what is being release all play a role in the release profile240, but most attempts to 
predict this behavior focus on a dominant erosion behavior.  In a non-degradable matrix, in vitro 
release studies show that matrix porosity controls the diffusion of protein through the matrix.241  
When the rate hydrolysis is much faster than the rate of water diffusion through the polymer 
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matrix, surface erosion is prominent.242  When water diffusion is so fast that the particle is 
completely hydrated before significant diffusion occurs (in the case of PLGA microspheres), 
bulk erosion occurs. 
Recently, a model that describes up to three phases of release (burst-lag-burst, Figure 14) 
for agents ranging in size from small molecules to viruses195 (and extended to matrix implants 
and hydrophobic agents196) has been developed.   This model takes five readily attainable 
parameters (polymer initial molecule weight, polymer degradation rate, microparticle size, initial 
drug distribution, drug molecular weight) into account when predicting release from a 
degradable microparticle system.243  These parameters are used to determine a new parameter 
known as the molecular weight of release (Mwr), which described the average polymer molecular 
weight that permits diffusion of the encapsulated agent and is dependent upon the size of the 
agent being released.195  Using these values, the magnitude of initial burst and release kinetics of 
subsequent stages could be predicted in a regression free manner.195  A modification to the model 
was made to include predictions that account for matrix hydration and dissolution kinetics.196  
These new considerations allow this model to be extended to surface eroding systems, as well as 
surface eroding systems that transition to bulk eroding systems.196  These finding allow for the 
tuning of the magnitude of initial burst, the lag phase and the final rate of release, so that a 
particular microparticle formulation could be conceived given a desired release profile and 
application.243 
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Figure 14.  Schematic of triphasic release from microparticle systems. 
 
 
Overall release time of a microparticle system is determined by the degradation rate of 
the polymer, however, it was found that each of the phases can be individually tuned.  It has been 
determined that the initial burst can be adjusted by changes in the initial drug distribution as well 
as the matrix size.243  Similarly, it has been determined that the lag phase can be adjusted by 
changing the polymer molecular weight and degradation rate.243  Lastly, the terminal release can 
be adjusted by changing the copolymer ratio.243  Development of a model that could predict the 
behavior of any microparticle set would allow for rapid development of tunable microparticles. 
Using this model as a tool, it can be envisioned that degradable particles that release 
factor 1 for a predetermined amount of time can be combined with separate degradable particles 
that are designed to “wait” until the other formulation has completed its release prior to the onset 
of factor 2 release.  If possible, such would represent an extremely attractive way to sequentially 
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deliver two growth factors in the same injectable system.  In the same way, it is possible that any 
number of other physiologically relevant release profiles, such as pulsatile kinetics, could be 
achieved through rational design of the degradable release formulations.   
Research is currently being performed, where microparticles that release an early stage 
angiogenic factor are combined with microparticles that exhibit delayed release, or no initial 
burst, followed by release of a late stage angiogenic factor according to delivery schedules 
discussed in Chapters 8.0  and 9.0 .  This combination of microparticles would produce a 
combined release profile of sequentially delivered angiogenesis promoting factors, and thus an 
injectable therapeutic alternative to current angiogenesis promoting treatments.  
7.6 CONCLUSIONS 
Release systems capable of unique and finely tuned release kinetics have potential in the fields of 
angiogenesis244, bone healing213, 245-248, hormone therapy192 and tissue regeneration98, 101, 249.  
Although many release systems are becoming increasingly relevant towards the development of 
temporal release systems that can mimic physiological processes, it is also important to 
determine the “ideal” release kinetics to achieve the desire response.  The remaining chapters 
will discuss how porous cellulose hollow fiber membranes can be used to gain a better 
understanding of four angiogenesis promoting factors and their involvement in each angiogenic 
stage.  This system allows for the exploration of many release profiles without fabrication of 
complex release systems.  Equipped with this information, the emerging delivery systems 
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described above can be “programmed” with the appropriate sequential release time-frames for 
specific biological applications. 
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8.0  SEQUENTIAL DELIVERY OF VEGF AND S1P 
8.1 INTRODUCTION 
As discussed previously (Section 4.1), some progress has been made towards the promotion of 
angiogenesis in vivo by delivery of various angiogenic growth factors.  Yet, delivery of a single 
factor alone (such as vascular endothelial growth factor, VEGF), is known to be associated with  
weak and leaky vessels.9  Consequently, it has been hypothesized that a combination of 
angiogenic growth factors might be the key to inducing functional, mature angiogenesis that 
integrates with the existing vasculature.9  Yet, the process of angiogenesis is an organized series 
of events, beginning with vessel destabilization, and followed by endothelial cell proliferation 
and migration, and lastly vessel maturation (Chapter 6.0).9  During these events, it is thought that 
different angiogenic factors become important at different points in time.64   
Certain factors have already been identified as playing a roles in a specific stage of 
angiogenesis, such as endothelial cell migration and proliferation9, vascular network maturation75 
and induce a proangiogenic phenotype in endothelial cells.71  Of these factors, VEGF and 
sphingosine-1-phosphate (S1P) are two with well documented and distinctive roles.  Although 
VEGF is known to mediate the recruitment of endothelial cells9, it has been observed that S1P 
(an angiogenic factor shown to stabilize intracellular junctions and decrease permeability of 
endothelial cells250-251), inhibits the recruitment of these endothelial cells. Furthermore, an 
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examination of S1P and VEGF signaling in endothelial cells suggests that there is a preferred 
sequence of factor presence and absence during the formation of mature vasculature102-103, 183, 252.  
In light of these data, it is reasonable to speculate that the logical strategy to stimulate growth of 
neovasculature would be to first induce recruitment of endothelial cells through VEGF (without 
inhibition from S1P), followed by the onset of endothelial cell arrangement and mural cell 
recruitment due to subsequent presence of S1P (without inhibition from VEGF).   In other words, 
exhibiting control over the absence of a given angiogenic factor may be just as important as 
control over the presence of that factor in a given stage of angiogenesis.  VEGF and S1P are an 
example of factors in which their temporal presence may affect their action on a particular 
physiological process. 
Controlled release is one viable strategy for achieving temporal presentation of small 
molecules and proteins in a format that can be applied therapeutically. Yet, to date, achieving 
such a complex release profile has proven elusive (Chapter 7.0).67, 139-140  For instance, dual 
delivery of basic fibroblast growth factor (bFGF) and VEGF253 as well as angiopoietin-1 and 
VEGF254 have been explored previously.  In these studies, angiogenic growth factors were 
loaded into the same scaffold so that release of these factors occurs simultaneously (e.g. dual 
delivery).  In addition, several attempts have been made to adjust the release of two factors 
independently (VEGF and PDGF), where each growth factor is loaded into a different scaffold 
(i.e. each factor is provided its own “resistance” to release over time).  Accordingly, VEGF and 
PDGF were released at different rates, leading to some observable differences in response.67, 213 
Yet, to study systems where the function of a growth factor may inhibit the function of another 
(e.g. angiogenesis), it would be desirable to develop a model where temporal separation of 
biomolecule release can be easily tuned. 
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Here, we describe a sequential delivery model based upon a porous hollow fiber that 
extends into an acellular site (in vitro or in vivo), permitting external control over presence and 
absence of angiogenic factors at any time.  In this model, a hollow fiber membrane separates the 
angiogenic factor “reservoir”, which resides in the lumen of the fiber, from a scaffold for cellular 
infiltration.  Due to the ease of accessibility to the hollow fiber lumen, this system is extremely 
modular, allowing for a quick change in factor delivery at any point in time.  The fiber wall 
microstructure can be controlled through the hollow fiber fabrication process to ensure that large 
proteins can be effectively released over time to the surrounding matrix.255-258  We have used this 
model to study the hypothesis that the sequence and delivery schedule of VEGF and S1P will 
impact the significance and maturity of angiogenesis, based on evidence that the presence of one 
factor might inhibit the performance of another factor. 
8.2 MATERIALS AND METHODS 
8.2.1 Hollow fiber fabrication and characterization 
Cellulose acetate hollow fibers were prepared using a double injection nozzle (14G/20G) and 
two syringe pumps (Braintree Scientific).  Twenty percent cellulose acetate (30kD, Aldrich) in a 
DMSO/acetone/isopropanol/water [49:15:15:1 weight%] was pumped through the outer core of 
the nozzle at 1.5mL/min and deionized water was pumped through the center core at 10mL/min.  
The cellulose solution and deionized water were extruded into a deionized water bath where the 
cellulose solution precipitates in the form of a porous hollow fiber, as previously described259, 
creating a flexible hollow fiber membrane capable of implantation into an animal.  Hollow fibers 
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were sterilized with UV light and stored in deionized water for future use.   Lyophilized hollow 
fiber cross sections were sputter coated with 3.5nm of gold-palladium and imaged at 5kV using a 
JEOL 9335 SEM. 
8.2.2 In vitro release 
Wells of a 6-well cell culture plate were filled with 3mL Dulbecco’s phosphate buffered saline, 
or PBS (Invitrogen) and a cellulose hollow fiber was cut to fit the well and injected with 10µL of 
rmVEGF (R&D Systems) and Fluorescein (Sigma) using a 28½G insulin syringe (1/2 cc Lo-
Dose U-100 insulin syringe, Becton Dickinson and Co.).  Hollow fibers were injected first with 
VEGF (100µg/mL) and subsequent release into a PBS bath was measured by sampling the 
supernatant and measuring using a VEGF ELISA kit (R&D Systems).  After 24 hours, the fiber 
was rinsed five times with PBS and lumen contents were replaced with an aqueous solution of 
fluorescein (1800µM).  Again, release was measured by sampling the supernatant and measuring 
fluorescence emissions every hour on a plate reader (SpectraMaxM5, Molecular Devices). 
8.2.3 Murine Matrigel plug assay 
Growth factor reduced Matrigel (500µL) was injected into the subcutaneous space on the dorsal 
side of C57BL/6 mice (8-10 weeks old, Charles River) on both the left and right flank, following 
anesthesia with 2-3% inhaled isoflurane.  After five minutes (to permit gelling), a 12G needle 
was used to thread cellulose hollow fibers through the skin and Matrigel plugs.  Hollow fibers 
were fixed in place using tissue glue and an Elizabethan collar was used to prevent mice from 
extracting the hollow fiber.  On the day of implantation and every day for the next 6 days, hollow 
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fibers on the left side were injected with sterile saline, as an internal negative control, and hollow 
fibers on the right side were injected with 10µL of an angiogenesis promoting factor: 100µg/mL 
VEGF (R&D) and/or 1800µM S1P.  For mice in the sequential delivery groups, factor switching 
occurred on the third day after implantation, following five rinses with saline.  Seven days post-
implantation, implants were extracted, fixed in 2% paraformaldehyde for 5 hours and 30% 
sucrose overnight and snap-frozen in liquid nitrogen.  Frozen sections (8µm) were stained with 
Hemotoxylin and eosin (H&E) and analyzed for endothelial cell migration and vessel formation. 
8.2.4 Immunofluorescence 
Frozen Matrigel Plug sections (8µm) were incubated with primary antibodies rabbit anti-CD31 
(Abcam) and Cy3-conjugated mouse anti-α-smooth muscle actin (Sigma) and secondary 
antibody goat anti rabbit Alexa Fluor 488® (Jackson Immuno).  Sections were also 
counterstained with Hoechst (Sigma) to identify all mononuclear cells.  Images of CD31 labeled 
cross-sections were taken at 40x.  These images were analyzed using threshold analysis on 
Metamorph to quantify the percent of each image occupied by CD31 staining.  These values 
were averaged to obtain a representative percent for each cross-section and normalized to the 
internal positive control in which only saline was delivered. 
8.2.5 Statistical analysis 
ANOVA was performed when assays contained more than one experimental group, as in the 
tubular formation assay (n=3) and Murine Matrigel plug assay (n=3).  Pilot studies and a power 
analysis were performed to determine N for in vivo experiments.  Subsequently, a post hoc 
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multiple comparison test was performed to compare means of different experimental groups 
(Holm-Bonferroni, α=0.05, k=4). 
8.3 RESULTS 
8.3.1 Hollow fiber fabrication 
To test our hypothesis, we required a delivery system capable of true, sequential release.  
A hollow fiber based system (in which both ends extend out from the site of delivery) would 
effectively accomplish this task as long as the wall porosity was made large enough to facilitate 
protein delivery.  Given that commercially available fibers typically have smaller pores that do 
not permit protein delivery over the required time scales, we chose to fabricate fibers in-house 
using a double injection extrusion/precipitation method.  Cellulose was chosen as a non-
biodegradable, but biocompatible material.  An SEM image of the hollow fiber wall shows the 
complicated pore structure consisting of both macropores (>10µm) and micropores (<1µm), 
where the micropores (being the rate limiting portion of delivery) control the rate of delivery 
from the lumen of the fiber to the surrounding environment (Figure 15a).  A higher 
magnification SEM image shows the interconnected pore structure (less than 1μm) of the 
cellulose hollow fibers (Figure 15b).  The hollow fiber wall thickness was 114±11µm and the 
inner diameter was 863±67 µm. 
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Figure 15.  Scanning electron images of cellulose hollow fiber. 
Double extrusion nozzle (14G/20G) extruded 20% cellulose at 1.5mL/min and water flowing at 
10mL/min. (a) Hollow fiber wall depicting porous structure of hollow fiber from lumen (L) 
outward.  The edges of the wall display marcopores (denoted as M) around 10µm in width and 
30-50µm in length. (b) The microporous voids (denoted as µ) of the remaining scaffold are less 
than 1µm. 
 
8.3.2 Sequential delivery of molecules of relevant size 
A hollow fiber-based release system was chosen to present factors sequentially because of the 
precision afforded through external regulation of the lumen contents over time.  For the purpose 
of ensuring that fibers are capable of sequential control, we chose to modulate the 
presence/absence of two factors in the lumen of the fibers over time: 1) vascular endothelial 
growth factor (VEGF, 45kDa) and 2) Fluorescein (376Da) as an easily detectible molecule of 
similar size and solubility to S1P (379Da).  Specifically, porous fibers were loaded with VEGF 
for an initial period of release, rinsed and then subsequently loaded with fluorescein.  Egress of 
these molecules through the fibers and into a surrounding saline solution is represented in 
Figure 16.  Importantly, when factors are exchanged (corresponding with saline flushing prior to 
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administration of a new factor, depicted by the dotted line), VEGF release decreases and 
fluorescein is subsequently detectable in the supernatant.  These results suggest that our fibers 
are readily capable of release of a growth factor sized protein as well as sequential delivery of 
two factors, as determined empirically. 
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Figure 16.  Release profile of sequentially delivered VEGF and Fluorescein. 
Release profile from a cellulose hollow fiber, where dotted line represents the time at which fiber 
was rinsed.  Following injection of VEGF (100µg/mL), release is sustained for 24 hours before 
the fiber is rinsed five times with PBS.  VEGF release drops after rinsing at 24 hours.  Injection 
of Fluorescein (1800µM) occurs at 24 hours, where release is sustained for 24 hours. 
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8.3.3 Endothelial cell recruitment and vessel formation 
A modified murine Matrigel plug assay was utilized to measure angiogenesis in response to 
various delivery regimens in vivo.  Specifically, a subcutaneous Matrigel plug serves as a cell-
free matrix that is amenable to cellular invasion.  A fiber is threaded through this plug to create a 
source for factor release to surrounding cells.  The ends of the hollow fiber remain exposed, 
giving access to the contents of the lumen of the fiber (and consequently what is released into the 
cell-free matrix) over the course of experimentation.  We explored delivery of: 1) VEGF alone 
(Figure 17b), 2) S1P alone (Figure 17d), 3) VEGF followed by S1P (Figure 17c), 4) S1P 
followed by VEGF (Figure 17e), and 5) dual delivery of VEGF and S1P (Figure 17f).  Each 
experimental group contained an internal negative control where saline alone was administered 
through an implanted fiber (Figure 17a) over the course of experimentation (7 days).  In the 
sequential delivery groups, factor exchange (when relevant) occurred at 3 days post-implantation 
(as endothelial cell recruitment and vessel formation has previously been observed as early as 2 
days in murine Matrigel plugs260).  Hemotoxylin and eosin stained sections (Figure 17a-Figure 
17f) reveal detectible cellular infiltration in all groups (purple nuclear stain).  However, cellular 
infiltration into the Matrigel is more prevalent in the plugs in which an angiogenic factor has 
been delivered (Figure 17b-Figure 17f).  Importantly, in the plugs where VEGF delivery was 
followed by S1P delivery, H&E staining not only reveals denser cells, but the presence of red 
blood cells are indicative of functional angiogenesis within the Matrigel plug (Figure 17c and 
Figure 17g).  This same result (the presence of red blood cells surrounded by mononuclear cells 
in a tubular formation) was sometimes seen in plugs in which VEGF or S1P were delivered alone 
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or together, but with much less frequency than in the group where VEGF delivery was followed 
by S1P delivery, as depicted in Figure 17. 
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Figure 17.  H&E images of murine Matrigel plugs where VEGF and/or S1P are delivered. 
Sequential delivery of VEGF and S1P results in cellular recruitment and functional angiogenesis 
in vivo. (a-f) H&E images of murine Matrigel plugs (scale bar=500µm). (a) Saline.  (b) VEGF 
(100µg/mL). (c) VEGF (100µg/mL), followed by S1P (1800µM).  (d) S1P (1800µM).  (e) S1P 
(1800µM), followed by VEGF (100µg/mL).  (f) VEGF (100µg/mL) and S1P together (1800µM).  
(d) Magnification of blood vessels observed when delivery of VEGF (100µg/mL) was followed 
by delivery S1P (1800µM), dotted line in (c) (scale bar=50µm). 
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Similar results were observed in the CD31 stained Matrigel plug sections (Figure 18a-
Figure 18f).  Generally, CD31+ staining was more prevalent in groups where angiogenesis 
promoting factors were delivered as compared to internal negative controls.  However, greater 
amounts of CD31+ staining were observed in plugs where VEGF-then-S1P or VEGF alone was 
delivered as compared to all other groups (Figure 18b and Figure 18c).  Additionally, we 
observed that in groups where VEGF delivery was followed by S1P delivery, endothelial cells 
had arranged into tubular structures that appear larger than that of a capillary, indicating that this 
delivery schedule is not only capable of promoting angiogenesis in the acellular matrix on the 
capillary level, but also a larger, more developed vascular network (Figure 18c).261 
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Figure 18.  CD31 Matrigel plug staining where VEGF and/or S1P are delivered. 
Delivery of VEGF followed by S1P results in a greater recruitment of CD31+ cells in vivo than 
other delivery schedules. (a-f).  Immunoflourscent staining of CD31 (green) and nuclei (blue) in 
Matrigel plug cross-sections, scale bar=100µm.  (a) Saline.  (b) VEGF (100µg/mL). (c) VEGF 
(100µg/mL), followed by S1P (1800µM).  (d) S1P (1800µM).  (e) S1P (1800µM), followed by 
VEGF (100µg/mL).  (f) VEGF (100µg/mL) and S1P (1800µM). 
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Figure 19.  CD31 quantification where VEGF and/or S1P are delivered.  
CD31 quantification based on Metamorph threshold imaging and normalization to a saline 
injected plug.  Percent areas of images covered by CD31 staining are averaged across all plugs.  
Negative control plug percent areas (saline injection, left flank) for each mouse was subtracted 
from the Experimental Group percent areas (right flank) for a normalized percent area for each 
mouse.  *significantly different when compared to all other groups (ANOVA, followed by 
Holm-Bonferroni correction for t-test of multiple comparisons, k=4, α=0.05) 
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A semi-quantitative method for endothelial cell migration was also performed using 
CD31 staining of Matrigel plug sections.  The percent area of images that were labeled with 
Alexa Fluor 488 (secondary antibody) was used to quantify CD31 expression in each sample.  
Images representing the entire periphery of the plug were recorded, and an average percent area 
was determined (Figure 19).  It is evident that statistically more CD31+ cells are observed in 
sections of the Matrigel plug treated with the VEGF-then-S1P regimen than in any other 
experimental group. 
8.3.4 Vascular maturation index 
A quantitative method was used for determining the maturation level of a vessel using CD31 and 
alpha smooth muscle actin (αSMA) staining of Matrigel plug explants (CD31 is present on 
endothelial cells and αSMA is present on mural cells).  The colocalization of these two cell types 
is indicative of mature vessels.262  Five, 60x areas in which CD31+ cells have arranged in a 
capillary-like structure were examined, and the percent of αSMA+ colocalization was recorded 
as the maturation index.262  In general, fluorescent images illustrate that αSMA colocalization 
with CD31 can be seen in Matrigel plugs in the following groups: VEGF-then-S1P (Figure 20b), 
S1P (Figure 20d) and S1P-then-VEGF (Figure 20e).  A magnified image of αSMA+ vessels from 
the VEGF-then-S1P group (Figure 20f) shows αSMA staining surrounding the CD31+ vessels.  
In the plugs where only VEGF was delivered, we see only CD31 positive cells and no αSMA 
positive cells (Figure 20a).  When VEGF and S1P are delivered together (dual delivery), both 
CD31 and αSMA positive cells have migrated into the Matrigel plug, but we did not observe 
substantial co-localization of these cells (representative image shown in Figure 20c).  The 
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maturation index (percent of vessels co-localized with αSMA+ cells) is highest when sequential 
delivery is utilized, specifically when VEGF delivery is followed by S1P delivery (Figure 21). 
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Figure 20.  CD31 and αSMA Matrigel plug staining where VEGF and/or S1P are delivered. 
Delivery of VEGF followed by S1P results in greater colocalization of CD31 and αSMA in vivo 
than other delivery schedules.  (a-e)  Immunoflourscent staining of CD31 (green), αSMA (red) 
and nuclei (blue) in Matrigel plug cross-sections (scale bar=100µm).  (a) VEGF (100µg/mL). (b) 
VEGF (100µg/mL), followed by S1P (1800µM).  (c) VEGF (100µg/mL) and S1P (1800µM). (d) 
S1P (1800µM).  (e) S1P (1800µM), followed by VEGF (100µg/mL).  (f)  Co-localization of 
CD31 and αSMA when delivery of VEGF (100µg/mL) was followed by delivery S1P (1800µM), 
dotted line in (b), scale bar=50µm. 
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Figure 21.  Maturation index where VEGF and/or S1P are delivered. 
Maturation index calculated by the percent of CD31+ blood vessel that are co-localized with 
αSMA staining in areas where CD31+ blood vessels were observed.  *significantly different 
when compared to all other groups (ANOVA, followed by Holm-Bonferroni correction for t-test 
of multiple comparisons, k=4, α=0.05) 
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8.4 DISCUSSION 
Controlled release systems capable of delivering single biological factors are common in medical 
therapies today263, while controlled release systems capable of delivering multiple factors either 
simultaneously or sequentially are under development as an active area of current research.  Fine 
control over sequential delivery would yield a number of therapeutic advantages including the 
added efficiency resulting from more accurately mimicking natural schedules of angiogenic 
factor presentation in situ.  To this end, studies have demonstrated dual protein release through 
fully implantable hollow fibers and/or scaffolds where the rate of release is controlled by the 
respective degradation rate of either the hollow fiber or the scaffold (or both).264-266  While these 
systems can effectively deliver a single factor or a combination of factors simultaneously at 
different rates, these systems are not capable of sequential delivery where the onset of delivery 
for one factor is accompanied by the simultaneous abrogation of release for the other factor.  The 
goal of our study was to create and utilize a system that is capable of exploring sequential 
delivery of multiple angiogenic factors to an acellular site that is conducive to endothelial cell 
invasion.   
Porous hollow fibers allow for sequential delivery of multiple factors to the surrounding 
environment as determined exclusively by the contents of the lumen at any time (as externally 
controlled by the user).  Figure 16 demonstrates the capability of these hollow fibers to 
sequentially deliver molecules of relevant sizes and solubility.  Further, the hollow fibers 
fabricated in this study have shown to be effective at delivering angiogenic factors over at least 
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1.25mm (radius of the Matrigel plug in vivo) at physiologically relevant concentrations in an 
externally controlled and sequential manner.  Using the hollow fibers fabricated in this study, 
linear release is not achieved nor necessarily required.  Instead, the majority of the release occurs 
over the first few hours following injection into the lumen of the fiber.  Importantly, the 
consequent factor exposure (over a few hours) to the physiological environment is longer than if 
the factors were injected as a bolus injection, and the orientation of factor release produces 
several key advantages over bolus injection.  Firstly, a concentrated solution of each factor has a 
high likelihood of toxicity if exposed to cells directly.267  Because the ends of the hollow fiber 
are exposed during this study, re-injection of each factor occurs each day in order to maintain 
release of each factor, achieving a predicted release similar to that depicted in Figure 22.  
Secondly, the hollow fiber sustains a gradient of growth factor originating from the surface of the 
fiber and extending out into the Matrigel plug, producing spatial based information that is 
required for the chemoattractive capacity of each factor.268  Indeed, in previous studies, when 
VEGF was incorporated directly into the Matrigel plug (100ng total), cellular infiltration was 
only observed at the perimeter of the plug (Figure 23), which is a great difference from what we 
see when a hollow fiber is used to deliver the growth factor from he center of the plug (Figure 
17). 
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Figure 22.  Projected in vivo release when injections occur daily. 
 
 
 
 
Figure 23.  H&E of Matrigel plug loaded with 100ng VEGF, 10x. 
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In vivo, it is possible that these fibers may experience more advanced membrane fouling 
than observed in our in vitro studies either due to protein accumulation in the Matrigel plug or 
cell-mediated barrier formation at the surface of the fiber.  The material used for the hollow 
fiber-based model, cellulose, was chosen to mitigate this risk as a biologically inert material.269  
Indeed, at the experimental endpoint of our studies, no cellular infiltration into the membrane or 
cellular adhesion onto the membrane surface was observed. Furthermore, on the time-scale of 
our studies, we did not observe that potential hindrances to diffusion were extensive enough to 
impair the cellular infiltration and vessel formation induced by both single-factor and (to a 
greater extent) sequential delivery.  Lastly, the point at which the fiber enters the skin may 
increase the risk for infection if administered clinically.  Although infections have not been 
observed in this study, it should remain a concern for future studies, where an animal model that 
might be more prone to infection may be utilized.  If therapeutic application for this technology 
is required, one potential solution would be to deliver antibiotics along with the growth factor.   
An externally controlled delivery system (such as the one described here) is important to 
studying the effects of angiogenic factors in vivo given that the alternative (bolus injections of 
“naked” factors) would result in rapid diffusion and immediate exposure of released agents to 
enzymes and other proteins that can lead to a dramatic loss of bioactivity (e.g. the half-life of 
VEGF in serum is 33.7 minutes142) and spatial gradients.  Hollow fibers, conversely, would 
sustain the release of angiogenic factors (originating from the fiber and extending out through 
extracellular matrix) over an extended period of time.  Our hollow fiber system (Figure 22h) 
allows for external control over delivery to an internal in vivo location.  Following a rinsing step, 
delivery of one factor can be “turned off”, while delivery of another factor is simultaneously 
 93 
“turned on” (Figure 16).  This setup allows us to test the hypothesis (for the first time) that 
sequential delivery will improve angiogenic response. 
Angiogenesis is an ideal regenerative process to explore the advantages of sequential 
delivery due to its well-studied, stage-wise nature.9, 270  Early stage angiogenic events include 
destabilization of existing vessels, as well as proliferation, migration and invasion, of activated 
endothelial cells.9  VEGF appears to be involved primarily in the initiation of angiogenesis67, 
playing a major role in vascular permeability and endothelial cell recruitment9.  This is consistent 
with our data indicating that VEGF efficiently recruits endothelial cells to a subcutaneous 
Matrigel plug (Figure 18b).  However (as discussed in more detail below), the promising early 
angiogenic events observed when VEGF was exclusively delivered did not progress further as to 
produce detectable maturation events.  Similarly, it has been shown elsewhere in long-term 
clinical trials that delivery of VEGF alone has led to unstable vessels.104, 271  Remarkably, these 
results are entirely consistent with studies that suggest that VEGF mediates cellular effects that 
are conducive to early-stage angiogenic events while being (by definition) inhibitory to later 
stage angiogenesis events.  Specifically, VEGF inhibits pericyte coverage of vascular sprouts by 
suppressing receptors on vascular smooth muscle cells, leading to existing vessel 
destabilization.252  Together, these data suggest that VEGF alone is likely insufficient to 
complete angiogenesis given its dual role as a promoter of endothelial cell function and a 
negative regulator of vessel maturation.102-103, 252   
In contrast, late stage angiogenesis events include inhibition of endothelial cell 
proliferation and migration, basement membrane secretion and pericyte recruitment.9  These 
events appear to be mediated (at least in part) through S1P and, as stated above, inhibited by 
VEGF.  It has also been shown that elevated levels of S1P can lead to a reduction in endothelial 
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cell migration via rearrangement of their cytoskeleton.182, 272  These observations are consistent 
with our data, showing the S1P delivery is less effective at recruiting endothelial cells when 
compared to VEGF (Figure 19, p=0.023).  Rather, S1P is released from activated platelets 
following injury and has been shown to promote vessel stabilization in vivo.74, 78  Indeed, the 
importance of S1P in vessel maturation is evident by the fact that knockout of the S1P receptor 
on endothelial cells S1P1 is embryonic lethal in mice due to severe hemorrhaging.92  Upon closer 
inspection, it was observed that these embryos were deficient in mural cells and vascular 
pericytes, causing microvessels to dilate and rupture.92  Furthermore, VEGF has been shown to 
not only upregulate the S1P receptor (S1P1) on endothelial cells183 but also to increase 
sphingosine kinase activity273, leading to the conversion of sphingosine to S1P.  For these 
reasons, it is logical to believe that late stage angiogenesis is characterized not only by the 
presence of S1P, but also the absence of VEGF.   
In addition, productive angiogenesis requires both recruitment of endothelial cells into an 
acellular site and assembly of these cells into patent, stable vessels.  A hallmark characteristic of 
stable (or mature) vessels is the presence of vascular pericytes supporting the endothelial cell 
structure.75, 252  Although microvascular pericytes are poorly understood274-275, their importance 
is demonstrated by the pathological phenotypes of mice with poor pericyte development.179, 276-
277  It is known that pericyte function occurs in relatively late microvascular development 
events274-275, corresponding to our data that suggests S1P (a factor known for vessel stabilization 
via activated endothelial cell recruitment of vascular pericytes cells93), is best delivered during 
late angiogenesis development.  When examining endothelial cell/pericyte colocalization, it was 
observed that the highest amount of colocalization occurred when VEGF delivery was followed 
by S1P delivery (Figure 20 and Figure 21).  This delivery schedule also resulted in the most 
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endothelial cell recruitment and tubular formation of these endothelial cells (Figure 18 and 
Figure 19).  Pericyte coverage of newly forming vasculature provides support and stability for 
these recruited endothelial cells.  As consistent with the literature cited above describing the 
cellular effects of VEGF and S1P, our results suggest that delivering S1P with VEGF diminishes 
the effects of both VEGF alone. 
Because of the versatility of our experimental model, dosing of VEGF and S1P can be 
optimized to result in quicker, more stable vessel formation.  Our sequential delivery regimen 
(Figure 17a) was based on reported evidence that endothelial cells can be recruited to a site and 
form vasculature is as little as three days260, as well as evidence for appropriate (physiologically 
relevant) concentrations of S1P and VEGF.78, 278  However, the cited literature references do not 
involve support of a growth factor gradient, which may affect the desired dosing.  Simply 
changing the injection timing and concentration can be used to examine the effects of altering the 
quantities released and the schedule and timing of that release.  Additionally, the hollow fiber 
porosity can be altered by changing key components in the fiber fabrication process, such as 
cellulose flow rate and cellulose concentration.  Furthermore, changing the porosity of the fiber 
wall leads to a change the rate at which factors are delivered.  For these reasons, our model can 
be used as a versatile tool to examine various delivery schedules for any given set of growth 
factors delivered sequentially.  Information obtained from these studies could pave the way for 
programming fully injectable, sequential delivery systems, a feat made feasible through recently 
published mathematical models that can direct the design and fabrication of biodegradable 
matrices to produce complex controlled release behavior.195-196 
Furthermore, this system can be used to explore sequential delivery of any number of 
different growth factors for therapeutic responses as well as for studying the biological events 
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leading to stage-wise regeneration of other tissues.  To this end, we are currently exploring the 
delivery of basic fibroblast growth factor, or bFGF, followed by PDGF.  These growth factors 
are also known to be involved with early and late stage angiogenesis events, respectively.67, 72-73, 
76  It has also be observed that bFGF induced tubular structures will regress over time in the 
absence of other signals.104  We believe that delivery of bFGF followed by PDGF will result in 
more mature, stable vessels than delivery of either factor alone as well as dual delivery of these 
factors.  It is also expected that sequential delivery of growth factors will prove to be relevant in 
other wound healing mechanisms, such as bone healing, in which delivery of an angiogenesis 
promoting factor like PDGF (that can inhibit osteoblast differentiation) would be followed by 
delivery of a bone morphogenic protein.279  
8.5 CONLUSION 
We have created a system capable of exploring true sequential delivery of angiogenic factors. 
When using this system to explore sequential delivery of VEGF and S1P for the purpose of 
promoting angiogenesis, we demonstrated that delivery of VEGF for 3 days followed by delivery 
of S1P for 4 days resulted in recruitment of more endothelial cells and a higher maturation index 
than the reverse sequential delivery schedule, single factor delivery or dual delivery.  This 
system can be used to explore any number of delivery schedules, allowing for a facile way to 
explore different delivery schedules of growth factors in vivo for therapeutic responses as well as 
for studying the basic biological signals that accompany stage-wise regeneration of tissues. 
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8.6 SUPPLEMENTAL INFORMATION 
8.6.1 Methods: Tubular formation assay 
HUVECs (Human Umbilical Vein Endothelial Cells, Lonza) treated with 100 µM Calphostin C 
(Calphostin C, Biomol International) for 30 minutes were cultured on Matrigel (Growth Factor 
Reduced Matrigel, BD Biosciences) in which a cellulose hollow fiber was embedded (200,000 
cells/well).  M199 containing 1%FBS and 600µM-1800µM S1P was injected into the hollow 
fibers.  After 16 hours of humidified cell culture at 37ºC and 5% CO2, cells were fixed with 2% 
paraformaldehyde (Fisher) and stained with rhodamine phalloidin (rhodamine phalloidin, 
Invitrogen, Eugene, OR) with 0.1% triton (Sigma).  Cultures were imaged using an Olympus 
Provis and quantification of tubular formation was performed by threshold analysis on 
fluorescent images (Metamorph). 
8.6.2 Results: Endothelial cell tubular formation following angiogenic factor release from 
hollow fibers through Matrigel in vitro 
An in vitro model was constructed to mimic several aspects of the three-dimensional release 
environment that would be encountered in vivo.  This system (as schematically represented in 
Figure 22h) permits the administration of a factor through a hollow fiber so that it will diffuse 
through a layer of Matrigel to cells that are seeded on top (e.g. representing a surrounding cell 
source at a wound site).  By observing Human Umbilical Vein Endothelial Cells, or HUVECs, 
on top of the Matrigel, we were able to demonstrate that S1P administered through the fiber is 
released and subsequently influences the behavior of surrounding cells.  Specifically, we 
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observed a dose-dependent response with respect to tubular formation (as measured by 
rhodamine phalloidin staining and fluorescence microscopy) (Figure 22a-Figure 22f).  These 
results suggest that delivery of a sparingly soluble agent is possible at relevant concentrations to 
cells at a distance (1.25mm) relevant to our in vivo model.  Quantification of cellular surface area 
using threshold analysis on Metamorph software, reveals a significant difference in tubular 
formation between the groups where a fiber is injected with 1200µM and 1800µM S1P when 
compared to a fiber injected with media alone (Figure 22g). 
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Figure 24.  Tubular formation assay with HUVECs and S1P. 
S1P released from hollow fibers affect HUVECs in a dose dependent manner in vitro.  
(a-f) Rhodamine phalloidin stained HUVECs on Matrigel, scale bar=15µm. (a) HUVECs on 
Matrigel in media resulted in alignment of endothelial cells.  (b) HUVECs seeded on Matrigel 
with media injected into fiber resulted in alignment of endothelial cells.  (c) HUVECs on 
Matrigel with 5µM S1P results in network formation of endothelial cells. (d) - (f) HUVEC 
exhibit a dose dependent response to S1P where an increase in the injected concentration of S1P 
increases the progression towards network formation of endothelial cells.  (g) Percent area 
covered by endothelial cell tubes, identified by rhodamine phalloidin staining and quantified 
with Metamorph threshold analysis. *p<0.05 when compared to media injected into fiber (one-
tailed t-test, n=3)   (h) Schematic of the in vitro setup allowing for externally controlled delivery 
of an angiogenic factor to an endothelial cell population through Matrigel. 
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9.0  SEQUENTIAL DELIVERY OF BASIC-FGF AND PDGF 
9.1 INTRODUCTION 
Considering the temporal complexity of angiogenesis, it is not surprising that strategies 
focusing on delivery only a single angiogenic factor43, 104-106 or even two angiogenic factors 
simultaneously71, 280 have met limited success.  In order to gain information regarding the most 
relevant time-frames, concentrations and growth factors, to be used in therapeutic sequential 
delivery strategies, we recently developed a simple and modular, externally-regulated delivery 
model (Chapter 8.0 ).281  This model consists of a porous hollow fiber that extends into an 
acellular site in vivo, permitting external control over presence and absence of angiogenic growth 
factors at any time.281  The fiber wall microstructure is controlled through the fiber fabrication 
process to ensure that large proteins could be effectively released to the surrounding matrix.255-258  
The ends of the hollow fiber remain exposed, providing access to the contents of the lumen of 
the fiber (and consequently what is delivered) over the course of experimentation.  Using this 
system, we were able to achieve sequential delivery of two different angiogenic “instructions”: 
1) vascular endothelial growth factor (VEGF; involved in vasculature 
permeability/destabilization67 and endothelial cell recruitment9) and 2) sphingosine-1-phosphate 
(S1P; promoting vessel stabilization in vivo74, 282 and involved in a reduction in endothelial cell 
migration182, 272).  In this prior study, when VEGF delivery was followed by delivery of S1P, we 
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observed significantly greater endothelial cell migration as well as substantial increases in vessel 
maturity, when compared to single or dual delivery of these factors.281  This data suggests that 
attempting to sequentially stimulate various stages of angiogenesis via the presence and absence 
of angiogenic factors is a step towards the development of more complex and relevant 
angiogenic therapies. 
Importantly, recent literature suggests that the concept of stage-wise delivery for 
angiogenesis has broader application than only VEGF and S1P.    An ideal angiogenic therapy 
would involve stage-wise delivery of all growth factors known to support cellular action during 
the corresponding stage of angiogenesis.  Examples of other growth factors involved in 
angiogenesis are bFGF and PDGF.  Specifically, bFGF (17kDa) has been shown to play a major 
role in the initiation (sprouting) of new capillaries in vivo.283  PDGF (25kDa) released from 
activated platelets9, promotes the maturation of blood vessels through the recruitment and 
support of mural cells, the supporting structure for blood vessels67, 76, among other actions.284-285  
However, when bFGF and PDGF are presented simultaneously in a modified Boyden chamber 
assay, bFGF significantly inhibits PDGF-induced smooth muscle cell migration and proliferation 
via the PDGF and bFGF receptors.280  Conversely, in a chick chorioallantoic membrane assay, it 
has also been shown that PDGF inhibits bFGF-induced angiogenesis.71  Taken together, this data 
suggests that not only the presence, but the absence of bFGF and PDGF expression play a role in 
vascular remodeling. 
For the reasons described above, a sequential delivery model was utilized to explore the 
delivery schedule of bFGF and PDGF, delivered alone, in sequence or together.  Accordingly, 
we hypothesized that sequential delivery (bFGF followed by PDGF) would impact the 
significance and maturity of angiogenesis. 
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9.2 MATERIALS AND METHODS 
9.2.1 Hollow fiber fabrication and characterization 
Cellulose acetate hollow fibers were prepared using a double injection nozzle as described 
previously.281  Briefly, twenty percent cellulose acetate (molecular weight=30kD, Aldrich) was 
pumped through the outer core of the nozzle and deionized water was pumped through the center 
core.  The cellulose solution and deionized water were extruded into a deionized water bath 
where the cellulose solution precipitates in the form of a porous hollow fiber.  Lyophilized 
hollow fiber cross sections were sputter coated with 3.5nm of gold-palladium and imaged at 5kV 
using a JEOL 9335 SEM. 
9.2.2 In vitro release 
In vitro release from cellulose hollow fibers was carried out as described previously.281  Briefly, 
wells of a 6-well cell culture plate were filled with 5 mL Dulbecco’s phosphate buffered saline, 
or PBS (Invitrogen).  A cellulose hollow fiber was cut to fit the well and then injected with 10µL 
of rh-bFGF (R&D Systems) and rh-PDGF (R&D Systems) using a 28G½ insulin syringe (1/2 cc 
Lo-Dose U-100 insulin syringe, Becton Dickinson and Co.) and submerged in the PBS bath.  
Hollow fibers were injected first with bFGF (200µg/mL, 2ng bFGF total).  Release of bFGF into 
a PBS bath was measured by sampling the supernatant and measuring using a bFGF ELISA kit 
(R&D Systems).  After 24 hours, the fiber was rinsed five times with PBS and lumen contents 
were replaced with an aqueous solution of PDGF (300µg/mL, 3ng PDHG total).  Again, release 
 103 
was measured by sampling the supernatant and measuring using a PDGF ELISA kit (R&D 
Systems). 
9.2.3 Murine Matrigel plug assay 
A modified murine Matrigel plug assay was utilized as described previously.281  Briefly, growth 
factor reduced Matrigel (500µL) was injected (approximately 1cm in diameter) into the 
subcutaneous space on the dorsal side of C57BL/6 mice (8-10 weeks old, Charles River) on both 
the left and right flank, following anesthesia with 2-3% inhaled isoflurane.  A 14G catheter was 
used to thread cellulose hollow fibers through the skin and Matrigel plugs.  Hollow fibers were 
fixed in place using tissue glue and an Elizabethan collar was used to prevent mice from 
extracting the hollow fiber.  On the day of implantation, and every day for the next 6 days, 
hollow fibers on the left side were injected with sterile saline (as an internal negative control) 
and hollow fibers on the right side were injected with 10µL of an angiogenesis promoting factor: 
200µg/mL bFGF (R&D) and/or 500µg/mL PDGF.  The internal negative control (which includes 
the Matrigel plug, hollow fiber and saline injection) serves the purpose of controlling for 
variation between mice (e.g potentially any variable growth factor secretion due to inflammation 
caused by the Matrigel injection or hollow fiber implantation).  For mice in the sequential 
delivery groups, factor switching occurred on the third day after implantation, following five 
rinses with saline.  Seven days post-implantation, implants were extracted, fixed in 2% 
paraformaldehyde for 5 hours and 30% sucrose overnight and snap-frozen in liquid nitrogen.  
Frozen sections (8µm) were stained with Hemotoxylin and eosin (H&E) and analyzed for 
endothelial cell migration and vessel formation, and red blood cell presence in vessel-like 
structures where the lumen is greater than 100µm. 
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9.2.4 Immunofluorescence 
Frozen Matrigel Plug sections (8µm) were incubated with primary antibodies rabbit anti-CD31 
(Abcam) and Cy3-conjugated mouse anti-α-smooth muscle actin (Sigma) and secondary 
antibody goat anti rabbit Alexa Fluor 488® (Jackson Immuno).  Sections were also 
counterstained with Hoechst (Sigma) to identify all mononuclear cells.  CD31 labeled cross-
section images were taken at 40x.  These images were analyzed using threshold analysis on 
Metamorph to quantify the percent of each image occupied by CD31 staining.  These values 
were averaged to obtain a representative percent for each cross-section and normalized to the 
internal positive control in which only saline was delivered.  Negative control plug percent areas 
(saline injection, left flank) for each mouse was subtracted from the Experimental Group percent 
areas (right flank) for a normalized percent area for each mouse.  CD31 and αSMA labeled 
cross-section images were taken at 60x.  These images were analyzed by counting the number of 
CD31 positive areas (vessel equivalents) and the number of these areas that are colocalized with 
αSMA labeling. 
9.2.5 Statistical analysis 
ANOVA was performed when assays contained more than one experimental group, as in the 
tubular formation assay (n=3) and Murine Matrigel plug assay (n=3).  A power analysis based on 
a previous, yet similar experiment was performed to determine N for in vivo experiments.  
Subsequently, a post hoc multiple comparison test was performed to compare means of different 
experimental groups (Holm-Bonferroni, α=0.05, k=4). 
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9.3 RESULTS 
9.3.1 Sequential bFGF and PDGF release from cellulose hollow fibers 
Cellulose hollow fibers were fabricated with an inner diameter of 971±129µm and wall thickness 
of 81±18µm (Figure 23a).  These fibers were used to sequentially release bFGF and PDGF in 
vitro, via manual injection of the growth factors at the desired timepoints.  Porous fibers were 
loaded with bFGF for an initial period of release, rinsed and then subsequently loaded with 
PDGF.  Egress of these molecules through the fibers and into a surrounding saline solution is 
represented in Figure 23b.  Importantly, when growth factors are exchanged (corresponding with 
saline flushing prior to administration of a new factor, depicted by the dotted line), bFGF release 
is no longer detectable and PDGF is subsequently detectable in the supernatant.  These results 
are in agreement with previous results281, suggesting that our fibers are capable of detectable 
release of a growth factor sized protein over at least 24 hours as well as sequential delivery of 
two factors, as determined empirically. 
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Figure 25.  Cellulose hollow fiber image and sequential release of bFGF and PDGF. 
Porous, cellulose hollow fibers are capable of sequential release.  (a) Scanning electron 
micrographs of a cellulose hollow fiber fabricated using a double extrusion process.  (b) Sample 
release profile representing sequentially deliver factors (dotted line represents the time at which 
fiber was rinsed).  Injection of bFGF (200µg/mL), allows for detectable release for 24 hours.  
Fiber is rinsed five times with PBS at 24 hours, resulting in a drop in detectable bFGF.  Injection 
of PDGF (300µg/mL) occurs at 24 hours, where release is detected for 24 hours. 
9.3.2 Recruitment of endothelial cells to Matrigel plugs in response to various treatment 
schedules 
A modified murine Matrigel plug assay was utilized to measure angiogenesis in response to 
various delivery regimens in vivo.  Specifically, a subcutaneous Matrigel plug serves as a cell-
free matrix that is amenable to cellular invasion.  A fiber is threaded through this plug to create a 
source for factor release through the Matrigel to the surrounding environment.  The ends of the 
hollow fiber remain exposed, giving access to the contents of the lumen of the fiber (and 
consequently what is released into the cell-free matrix) over the course of experimentation.  We 
explored delivery of: 1) bFGF alone (Figure 24b), 2) bFGF followed by PDGF (Figure 24c), 
3) PDGF alone (Figure 24d), 4) PDGF followed by bFGF (Figure 24e), and 5) dual delivery of 
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bFGF and PDGF (Figure 24f).  Each experimental group contained an internal negative control 
where saline alone was administered through an implanted fiber (Figure 24a) over the course of 
experimentation (7 days).  In the sequential delivery groups, factor exchange (when relevant) 
occurred at 3 days post-implantation.  CD31 stained Matrigel plug sections (Figure 24a-Figure 
24f) reveal endothelial cell infiltration in all plugs where growth factors (bFGF and/or PDGF) 
are delivered.  However, greater amounts of CD31+ staining were observed in plugs where bFGF 
was followed by PDGF as compared to all other groups (Figure 24c).  A semi-quantitative 
method for endothelial cell migration was also performed using CD31 staining of Matrigel plug 
sections.  The percent area of images that were labeled with Alexa Fluor 488 (secondary 
antibody) was used to quantify CD31 expression in each sample.  Images representing the entire 
periphery of the plug were recorded, normalized to the internal negative control and an average 
percent area was determined (Figure 25).  Basic FGF was shown to be active when delivered, 
demonstrated by an increase in endothelial cell recruitment when compared to a saline injection 
(Figure 24b and Figure 25).  It is evident that statistically more CD31+ cells are observed in 
sections of the Matrigel plug treated with the bFGF-then-PDGF regimen than in any other 
experimental group. 
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Figure 26.  CD31 Matrigel plug staining where bFGF and/or PDGF are delivered. 
Delivery of bFGF followed by PDGF results in greater recruitment of CD31+ cells in vivo than 
other delivery schedules. (a-f).  Immunofluorescent staining of CD31 (green) and nuclei (blue) in 
Matrigel plug cross-sections (scale bar=100µm) treated with: (a) Saline.  (b) bFGF (200µg/mL). 
(c) bFGF (200µg/mL), followed by PDGF (500µg/mL).  (d) PDGF (500µg/mL).  (e) PDGF 
(500µg/mL), followed by bFGF (200µg/mL).  (f) bFGF (200µg/mL) and PDGF (500µg/mL).  
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Figure 27.  CD31 quantification where bFGF and/or PDGF are delivered. 
CD31 quantification as normalized to an internal control (saline injected plug) using Metamorph 
threshold analysis.  Percent areas of images covered by CD31 staining are averaged across all 
plugs.  *indicates significant differences when compared to all other groups (ANOVA, followed 
by Holm-Bonferroni correction for t-test of multiple comparisons, k=4, α=0.05) 
 
 
9.3.3 Vessel maturation in response to various treatment schedules 
A quantitative method was used for determining the maturation level of a vessel using CD31 and 
αSMA staining of Matrigel plug explants (CD31 is present on endothelial cells and αSMA is 
present on mural cells).  The colocalization of these two cell types is indicative of mature 
vessels.262  This method involves immunohistochemical analysis of CD31 and αSMA stained 
tissue sections and is a common and validated measure of vessel maturity144, 213, 281, 286.  Five, 60x 
areas in which CD31+ cells have arranged in a capillary-like structure were examined, and the 
percent of αSMA+ colocalization was recorded as the maturation index.262  In general, 
fluorescent images illustrate that αSMA colocalization with CD31 can be observed in all plugs 
where PDGF was delivered (Figure 26b-Figure 26e).  In the plugs where only bFGF was 
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delivered, we could detect only CD31 positive cells and no αSMA positive cells (Figure 26a).  
The maturation index (percent of vessels co-localized with αSMA+ cells) associated with the 
sequential delivery groups was statistically higher than all other groups in our study, specifically 
when bFGF delivery is followed by PDGF delivery (Figure 27). 
 
 
 
 
Figure 28.  CD31 and αSMA Matrigel plug staining where bFGF and/or PDGF are 
delivered. 
Delivery of VEGF followed by S1P results in greater colocalization of CD31 and αSMA in vivo 
than other delivery schedules.  (a-e)  Immunoflourscent staining of CD31 (green), αSMA (red) 
and nuclei (blue) in cross-sections off Matrigel plugs (scale bar=100µm) treated with:  (a) bFGF 
(200µg/mL). (b) bFGF (500µg/mL), followed by PDGF (500µg/mL).  (c) PDGF (500µg/mL). 
(d) PDGF (500µg/mL), followed by bFGF (200µg/mL).  (e) bFGF (200µg/mL) and PDGF 
(500µg/mL). 
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Figure 29.  Maturation index where bFGF and/or PDGF are delivered. 
Maturation index calculated by the percent of CD31+ cellular structures that are co-localized 
with αSMA staining.  *indicates significant differences when compared to all other groups 
(ANOVA, followed by Holm-Bonferroni correction for t-test of multiple comparisons, k=4, 
α=0.05) 
 
 
9.3.4 Integration of neovasculature with native vasculature 
Hematoxylin and eosin stained sections (Figure 28a-Figure 28f) reveal detectible cellular 
infiltration in all groups (purple nuclear stain).  However, cellular infiltration into the Matrigel is 
more prevalent in the plugs in which an angiogenic factor has been delivered (Figure 28b-Figure 
28f).  Cells that have infiltrated into the Matrigel plug have arranged in tubular, vessel-like 
structures in plugs where PDGF is delivered alone (Figure 28d), following bFGF (Figure 28c) or 
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at the same time as bFGF (Figure 28f).  However, when bFGF is delivered alone (Figure 28b) or 
following PDGF (Figure 28e), vessels are not observed.  More importantly, tubular, vessel-like 
structures are filled with red blood cells only in groups where bFGF delivery is followed by 
PDGF (indicated by filled in arrow), suggesting integration with native vasculature (Figure 28c).  
The presence of red blood cells in the lumen of invading vessels was quantified by random 
selection of 10 vessel-like structures (lumen exceeding 100µm in diameter) using multiple wide-
field 20x images from each experimental group.  The number of these vessel-like structures 
filled with red blood cells in each group was identified and statistical analysis was performed in 
order to estimate the percent of invading vessels that are functionalized (i.e. Integrated with 
existing vasculature) (Figure 29).  It was quite obvious from both visual inspection of numerous 
H&E images (Figure 28) as well as quantitative data (Figure 29) that when bFGF delivery is 
followed by PDGF delivery, there are dramatically higher numbers of red blood cell filled 
lumens than in any other schedules in which vessel-like structures (lumen >100µm) were 
observed. 
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Figure 30.  H&E images of murine Matrigel plugs where bFGF and/or PDGF are 
delivered. 
Sequential delivery of VEGF and S1P results in cellular recruitment and functional angiogenesis 
in vivo. (a-f) H&E images of murine Matrigel plugs (scale bar=500µm). (a) Saline.  (b) bFGF 
(200µg/mL). (c) bFGF (200µg/mL), followed by PDGF (500µg/mL).  (d) PDGF (500µg/mL).  
(e) PDGF (500µg/mL), followed by bFGF (200µg/mL).  (f) bFGF (200µg/mL) and PDGF 
(500µg/mL).  indicates red blood cell filled vessels.   indicates empty vessels. 
 114 
 
 
Figure 31.  Vessel integration quantification when bFGF and/or PDGF are delivered. 
Percent of vessel-like structures (lumen>100µm) filled with red blood cells.  *indicates 
significant differences when compared to all other groups (ANOVA, followed by Holm-
Bonferroni correction for t-test of multiple comparisons, k=3, α=0.05) 
 
 
9.4 DISCUSSION 
While the physiological effects of many growth factors are generally known, in some specific 
tissues, the combination and interactions of the growth factors are only recently being explored.  
In recent literature, the most cited of these tissues is bone, where researchers are exploring 
delivery of angiogenesis inducing factors as well as bone morphogenic proteins.287-288  In the 
context of angiogenesis, it has recently been shown that delivery of an early-stage, endothelial 
cell recruitment factor, VEGF, before delivery of a late-stage, mural cell recruitment factor, S1P, 
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results in more overall endothelial cell recruitment as well as a higher vessel maturity, than when 
these factors are delivered together.281  Accordingly, VEGF and S1P may act as a series of 
“instructions” to sequentially promote separate stages of the process.  Yet, it is likely that other 
known angiogenic growth factors are involved in this series of sequential “instructions” as well.  
The goal of this study was to extend our sequential delivery model to study two other factors that 
have been implicated in stage-wise stimulus of blood vessel growth, namely bFGF and PDGF.  
Consequently, the knowledge gained from this research could serve as valuable additions to our 
understanding of the stage-wise process of angiogenesis as well as advancing therapeutic 
approaches to promoting angiogenesis. 
Although the externally-regulated delivery model used in this study is not autonomously 
capable of sequential delivery itself, it provides a flexible format for temporal separation of 
various growth factors over any desired timeframe.  Thus, a primary benefit of the model system 
discussed here is to inform the design of future systems that are capable of autonomously 
delivering these growth factors over a successful delivery schedule. Furthermore, the system 
allows for the introduction of a growth factor in a more gradual method than via bolus injection 
(a method previously proven to be effective281), where uniform distribution of a growth factor at 
non-toxic levels would be extremely difficult.  A second feature of this model system is the 
internal negative control.  Specifically, a matching Matrigel plug with implanted hollow fiber is 
present on the left flank of each animal enrolled in this study.  This Matrigel plug was analyzed 
for angiogenesis in the same fashion as the Matrigel plugs in the experimental groups so that the 
level of angiogenesis cause by the Matrigel injection as well as the hollow fiber implantation can 
be monitored.  Although endothelial cell migration levels in the internal controls are consistently 
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very low and often negligible (Figure 24a), the level of endothelial migration observed in each 
mouse was used to normalized all reported results (Figure 25). 
Basic FGF has been implicated in endothelial cell migration and has also been known to 
induce a proangiogenic phenotype in endothelial cells.71 This paradigm is consistent with our 
data suggesting that endothelial cell migration occurs to a greater extent when bFGF is delivered 
for 7 days as compared to saline controls (Figure 24a and Figure 24b) despite the fact that bFGF 
is found to be unstable in the presence of many proteases expected to be present under 
inflammatory conditions.289-291  However, it has been shown that bFGF can inhibit PDGF-
induced smooth muscle cell migration and proliferation via the PDGF and bFGF receptors280, 
events that correspond with late-stage angiogenesis. In agreement with these prior findings, our 
results suggest that exclusive, persistent delivery of bFGF results in endothelial cell migration 
(marked by CD31+ cells, Figure 24b) without colocalization with vascular pericytes (marked by 
αSMA+ cells, Figure 26a). These data suggest that delivery of bFGF alone is not sufficient to 
sustain (and may even inhibit the progress) of growing neovasculature, a theory supported by a 
recent study in mice.292  It is possible that the role of bFGF may be primarily limited to 
promotion of early stage-angiogenic events. 
PDGF, in contrast, is known to promote the maturation of blood vessels through the 
recruitment and support of mural cells.67, 71  Likewise, we observe that in all groups where PDGF 
is delivered, there is an increased presence of αSMA+ and CD31+ cell colocalization, regardless 
of the time-frame of delivery (Figure 26).  These data are important given that the process of 
pericyte coverage is imperative to the stability, and in turn the fate, of newly forming vessels.292  
Importantly, although newly forming vessels can be transient, and often regress292-293, such blood 
vessels are known to not contain αSMA positive cells which (when present) interact with, and 
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stabilize endothelial cells and inhibit regression.294  This process begins only once endothelial 
cells have been recruited and new basement membrane is secreted.9  It is not surprising then that 
the presence of PDGF, through its binding to PDGF-Rα on endothelial cells, negatively affects 
the action of bFGF – mediated recruitment.71 
For the reasons described above, we hypothesized that the delivery of bFGF should 
precede delivery of PDGF to best promote the growth of stable and mature neovasculature.  
Using our simple and flexible hollow fiber model for sequential delivery, this delivery schedule 
(bFGF, followed by PDGF) could be compared to delivery of each factor alone, dual delivery of 
both factors, as well as the reverse schedule (PDGF, followed by bFGF).  A sequential delivery 
schedule (in contrast to dual delivery) would support bFGF induced endothelial cell migration 
and proliferation without inhibition by PDGF, followed by PDGF induced vessel maturation, 
without inhibition by bFGF.  Accordingly, this delivery schedule resulted in both greater overall 
endothelial cell presence in a Matrigel plug after 7 days (Figure 24) as well as a higher 
maturation index of vessels formed by these endothelial cells (Figure 26). 
It was observed that delivery of bFGF and PDGF alone, as well as together induced 
similar levels of endothelial cell recruitment (Figure 24g).  It is important to note that while 
bFGF and PDGF may have conflicting effects on the recruitment and organization of both 
endothelial cells and vascular pericytes, complete inhibition of angiogenesis is not observed 
when both factors are added together (Figure 24f and Figure 26f).  This can possibly be 
explained by the pluripotency of PDGF.295-296  Although PDGF has been shown to be involved in 
mural cell recruitment and other late stage angiogenesis events178, it is also the only growth 
factor involved in FDA-approved treatment for non-healing wounds, suggesting that its effects 
may not be limited to one stage of angiogenesis.12  Regardless, this treatment is only 30% 
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effective10 and likely not capable of optimally directing a multi-stage process without the 
direction of other biomolecules. 
The need for additional biomolecular input for functional angiogenesis is evident our 
data.  Endothelial cells are recruited to the Matrigel plug when PDGF is delivered during early 
angiogenesis (first 3 days, Figure 24d and Figure 24f), but these vessels are not interconnected 
with existing vessels (as indicated by their lack of red blood cells in the vessels) (Figure 28d, 
Figure 28f and Figure 29).  While endothelial cell migration and vessel maturation are important 
in angiogenesis, vessels do not become functional until they are integrated with the native 
vasculature.  One way of determining whether or not a new vessel has integrated with the host’s 
existing vessels is by looking for the presence of red blood cells.  Only in plugs where PDGF 
delivery follows bFGF delivery (Figure 28c and Figure 29) did we consistently observe red 
blood cells in the lumen of these structures.  This suggests that this growth factor delivery 
schedule allows for more proper formation of vessels that are integrated with the native 
vasculature, allowing oxygen and nutrient delivery to newly forming tissue.  It is possible that 
constitutive delivery of PDGF does not allow for destabilization of native vessels to the extent 
necessary to allow juncture with newly forming vessels.  Although PDGF may not be capable of 
inhibition of endothelial cell migration and proliferation (as seen in Figure 24d), PDGF might 
block the act of basement membrane destabilization.71 
Though not discussed, there are additional methods for determining interconnectivity of 
newly forming vessels.  One method is through dextran-FITC injection into the tail vein of the 
mouse, followed by Matrigel plug recovery, as described previously.260, 297  This method allows 
for visualization of vessels (via FITC illumination) and quantification of vessel volume.  
Visualization of the new blood vessels may also allow for examination of “leaky” or 
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hemorrhagic vessels, which would be an indication of an integrated, but immature vessel.  Vessel 
volume can be determined through FITC concentration measurements following digestion of the 
Matrigel plug.  Due to the nature of our system, cellular infiltration as well as angiogenesis 
occurred rapidly, resulting in quick degradation of the Matrigel plug and incorporation of the 
implant with the surrounding tissue.  When attempting to isolate the Matrigel plug for FITC 
quantification following Dextran-FITC tail vein injection, it was difficult to determine where the 
Matrigel plug ended and where the native tissue began.  For this reason, only red blood cell filled 
lumen counts (Figure 31) were analyzed. 
Because our model is modular and easily tuned, sequential delivery of a wide variety of 
factors is possible.  To date, bFGF and PDGF is now the second set of growth factors that have 
been shown to be temporally relevant in mature angiogenesis using our sequential delivery 
model.  Additional growth factors can be explored in other wound healing models, as temporal 
relevance of growth factors is likely not unique to angiogenesis.  For example, platelet derived 
growth factor (PDGF) and bone morphogenetic protein 2 (BMP-2) have been implicated as 
playing a major role in the osteogenic processes; however, each protein appears to accomplish 
different tasks during different stages in the regeneration of bone.298-300  For instance, PDGF 
appears to aid in cellular recruitment, differentiation and proliferation, as well as angiogenesis, 
while BMPs seem to play a key role in the development of mature osteoblasts and bone tissue 
formation.301  Furthermore, PDGF has been shown to actually inhibit mature osteoblast activity 
in the later stages of bone formation.287 Hence, an ideal delivery strategy would first present 
early stage factors to induce angiogenesis and recruit osteoprogenitors and then present later 
stage factors to differentiate cells and induce mineralized tissue formation. 
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9.5 CONCLUSION 
We have created a flexible model for the study of sequentially delivered angiogenic factors. 
When using this system to explore sequential delivery of bFGF and PDGF, we observed that 
delivery of bFGF for 3 days followed by delivery of PDGF for 4 days resulted in recruitment of 
more endothelial cells and a higher maturation index than the reverse sequential delivery 
schedule, single factor delivery or dual delivery.  Additionally, sequential delivery of bFGF 
followed by PDGF resulted in vasculature that has integrated with the native vasculature, 
allowing for oxygen delivery to a previously cell-free environment.  This approach could be 
likewise utilized to explore any number of delivery schedules and the resulting therapeutic 
responses as well as for studying the basic biological signals that accompany stage-wise 
regeneration of tissues. 
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10.0  MODELING RELEASE FROM POROUS HOLLOW FIBERS 
10.1 INTRODUCTION 
Hollow fiber membranes have widespread use in industries such as food, juice, pharmaceutical, 
metal working, dairy, wine and most recently municipal drinking water.302-312  Depending on the 
application, hollow fiber membranes can be highly practical and cost effective alternatives to 
conventional chemical and physical separation processes due to their high surface area to volume 
ratio.  In the separation technology field, large volumes can be filtered, while utilizing minimal 
space, with low power consumption.313-314 
Recently, in the field of drug delivery, hollow fibers have been shown to be capable of 
growth factor delivery both in vitro74, 265-266 and in vivo106, 264, 315.  This concept was recently 
extended by using hollow fibers as a platform for sequential delivery of growth factors that are 
specific for angiogenesis.281  First, factors involved in early stages of angiogenesis were 
delivered to facilitate blood vessel destabilization and endothelial cell recruitment and 
proliferation.  Subsequently, factors involved in late stages of angiogenesis were delivered to 
facilitate mural cell recruitment and blood vessel stabilization.  The hollow fibers can extend into 
an acellular site or a wound, permitting a fine level of control over release as a function of time 
by externally manipulating the contents of the fiber lumen.  Such a platform could also be readily 
applied to delivery of growth factors associated with other physiological processes, such as bone, 
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where an angiogenic growth factor’s presence prior to a bone morphogenic growth factor can 
enhance bone healing.246, 248, 316 
Externally-regulated delivery (such as with hollow fibers) provides a flexible template 
that is well-suited to facilitate a better understanding of which growth factors are necessary at 
various stages of a physiological process, without the time and cost associated with more 
complex delivery strategies.  One of the primary reasons for this flexibility is that the rate of 
delivery is determined solely by the characteristics of the hollow fiber (pore size, wall thickness, 
etc.) and the composition and concentrations of agents in the fiber lumen.  This rate can be 
determined experimentally, in a similar fashion to other growth factor delivery systems, tracking 
in vitro release into a saline solution.  Modeling release of biologics from these hollow fibers 
would facilitate the design of delivery regimes with even less cost of time and money as well as 
allowing the exploration of the feasibility of any number of complex release profiles. 
In order to model release of biomolecules from hollow fibers, a basic understanding of 
associated release mechanisms is in order.  Protein transport through polymer matrices can often 
be rudimentally described by Fick’s law of diffusion, under the assumption that the diffusivity of 
each protein does not change over time, where a protein will travel from an area of high 
concentration to low concentration with a rate dictated by its constitutive diffusion coefficient 
(D) and the extent of concentration driving force.  However, when recombinant proteins are 
loaded at a very high concentration (in conjunction with processing excipients) into a hollow 
fiber, other phenomena may also arise.  For instance, proteins, such as the ones delivered for 
angiogenesis,281 have isoelectric points between 9 and 10.  For this reason, at high 
concentrations, the negatively charged proteins increase the osmolality of the solution.  An even 
greater impact on the osmolality of the protein solution lies within the processing method, where 
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the excipients used to process and isolate the recombinant protein varies.  With a high 
osmolality, an osmotic pressure difference is created between the lumen of the protein loaded 
fiber, and the surrounding physiologic environment.  The osmotic pressure difference that 
develops between the hollow fiber and its surrounding environment causes an influx of water to 
the fiber, decreasing the lumen concentration and increasing the lumen volume.  The increase in 
volume, in turn, creates a hydrostatic pressure difference that causes a net flux of water, and thus, 
protein, out of the fiber.317  Therefore, both diffusion as well as osmosis-driven convection must 
be considered with modeling release from porous hollow fibers. 
Accordingly, this work describes the development of a mathematical model that can 
predict the release of VEGF, bFGF or PDGF, from cellulose hollow fibers fabricated under 
varying conditions.  This model takes into consideration, not only the flow of proteins due to 
diffusion, but also convection caused by bulk flow of water.318  Model predictions were 
compared to in vitro release data, where protein release into a saline bath was measured. 
10.2 THEORY AND MODEL DEVELOPMENT 
10.2.1 Diffusion 
Hollow fibers fabricated using a double injection nozzle often have both large macropores (Mp) 
as well as small micropores (µp), as a result of solvent extraction and spinodal decomposition256 
(Figure 30, left).  Diffusion of a large molecule such as a protein through a polymer matrix can 
rudimentarily described by Fick’s law of diffusion, where transport of a molecule is governed by 
the concentration difference and the individual diffusivity for a given molecule/solvent 
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combination.  When using Fick’s law to predict protein release from a hollow fiber membrane, 
the overall cross-sectional area for diffusion can be approximated by two separate “paths” that 
the molecule can take (Figure 30, right).  In the first path, the protein would travel through only 
the microporous section of the hollow fibers, where the micropore porosity would contribute to 
the transport rate.  Alternately, in the second path, the protein would travel through a 
combination of microporous and macroporous regions, where the micropore porosity as well as 
the size and geometry of the macropores would both contribute to the transport rate.  The number 
of molecules that travel through path 1 versus the amount of molecules that travel through path 2 
can be predicted by the height of the macropores compared to the distance between them, where 
j1 is the fraction of path 1 (Equation 1), but also with consideration of available surface area and 
the molecule’s preference for a path of least resistance (path 2). 
 
 
 
 
Figure 32.  Hollow fiber schematic and model theory. 
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Equation 1   
 
The transport resistance through path 1 and path 2 (individual porous matrices) can be 
determined by the porosity of each of these paths, where transport through a single macropore 
would have a porosity of 1.  The ratio of macropore distance of diffusion to micropore distance 
of diffusion can be determined by the width of the macropores.  Based on diffusion by Fick’s 
law, the concentration in the lumen of the hollow fiber can be calculated according to Equation 
2, where C0=concentration in the hollow fiber lumen (µg/mL), Vhf=equals the volume of solution 
in the hollow fiber lumen (mL), β=diffusivity determined by specific hollow fiber characteristics 
and molecule diffusion coefficient (cm/s) and t=time (s). 
 
Equation 2   
  
10.2.2 Osmotic and hydrostatic pressure 
When predicting transport across a membrane, it is necessary to also consider the osmolality of 
the solutions on both side of the membrane.  A difference in osmolality, and thus osmotic 
pressure difference, will cause transport of water across the membrane in the direction of high 
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osmolality.  This process is known as osmosis, defined as the solvent diffusion through a semi-
permeable membrane.319-320 
Mass transport can be driven by osmotic pressure, hydrostatic pressure or in some cases 
both.321-322  Volume flux due to osmosis can be described as derived by Kedem and Katchalsky 
(Equation 3), where this relationship can be represented as linear relationship between force and 
flow (Jv=solvent volume flux (m/s), Lp=filtration coefficient (m3/N•s), P=hydrostatic pressure 
(Pa), σ=reflection coefficient, π=osmotic pressure (Pa)).319   
 
Equation 3    
 
10.2.3 Model 
The goal of this model is to calculate transport across a porous membrane through modeling of 
the processes of diffusion and convection based on solvent flux.  The diffusivity of each protein 
can be estimated from the diffusivity of the protein in water (D, as reported in previous studies) 
and the porosity (ε) of each hollow fiber (Equation 4).  If the porosity is 1 (such as in a 
macropore), the diffusivity of an agent will be equal to the diffusivity of that agent in water 
(Equation 5). 
 
Equation 4    
Equation 5    
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The geometry of the hollow fiber wall is used to determine transport across the 
membrane.314  This calculation is based on Fick’s law, under the assumption of the following 
boundary conditions: 
1:   
2:   
3:   
4:   
and the following flux equations: 
1:   
2:   
3:   
Using the above boundary conditions, β in Equation 2 can be calculated (Equation 6), 
where Dµp=diffusivity of the molecule through the micropores (cm2/s), DMp=diffusivity of the 
molecule through the macropores (cm2/s), j1=fraction of molecules traveling through micropores 
(path 1), j2=fraction of molecules traveling through macropores (path 2), W=thickness of hollow 
fiber wall (cm) and δ=macropore width (cm).  Equation 6 can be applied to Equation 2, leading 
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to a final equation for the concentration within the hollow fiber, with respect to time (Equation 
7), when considering transport by diffusion only. 
 
Equation 6    
Equation 7    
 
 
Volume flux of water into and out of the fiber can be calculated according to Equation 3.  
The osmolality of each solution can be measured experimentally in order to determine a linear 
relationship between osmolality and concentration.  The hydrostatic pressure can be calculated 
according to Equation 8, where ρ is the density of the solution (kg/m3), g=9.81m/s2 and h=height 
of the solution (m).  The density of the solution can be estimated as the density of water (any 
weight that can be attributed to the weight of the protein is considered negligible). 
 
Equation 8   
  
 
The filtration coefficient (Lp) is a measure of a membrane’s permeability to water, with a 
higher permeability correlating to a higher porosity and a thinner membrane.323  Theoretically, 
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the filtration coefficient value represents the membrane surface area as well as hydraulic 
conductance and can be calculated according to Equation 9, where ε=porosity, r=pore radius, 
µ=viscosity and τ=tortuosity.  In this equation, it is assumed that the porosity of the membrane is 
uniform. 
 
Equation 9    
 
In the case of hollow fiber membranes with both micropores and macropores (as depicted 
in Figure 30), the water permeability through the macropores will be substantially greater than 
the micropores (macropore radius~10-50µm versus micropore radius~0.25-0.5µm).  For this 
reason, the filtration coefficient can be estimated as a function of the macropore size alone. 
The reflection coefficient relates to how a semipermeable membrane can reflect solute 
particles that could otherwise pass through and is sometimes viewed as a “correction factor”.  A 
value of zero results in all particles passing through, while a value of one is such that no particle 
can pass.319, 324  For this reason, the reflection coefficient can be estimated as a function of the 
porosity of the membrane. 
Taken together, the solvent flux can be calculated from Equation 3, where the osmotic 
pressure is a function of the concentration in the hollow fiber lumen and the hydrostatic pressure 
is a function of the volume in the hollow fiber lumen.  If the hydrostatic pressure is great enough 
that the solvent flux is positive (resulting in bulk flow out of the fiber), the bulk flow will contain 
solute and thus contribute to overall transport.  The overall transport will amount to the sum of 
the amount released via diffusion and the amount released via solvent flux. 
 130 
10.3 METHODS AND MATERIALS 
10.3.1 Hollow fiber fabrication 
Cellulose acetate hollow fibers were prepared using a double injection nozzle (inner tube=20G, 
outer tube=14G).  Cellulose acetate (30kD, Aldrich) was dissolved at a final concentration of 
49.67% DMSO, 14.67% acetone, 14.67% isopropyl alcohol, 1% water and 20% cellulose 
acetate, and was pumped with syringe pumps (Braintree Scientific) through the outer tube of the 
nozzle (14G), and deionized water was pumped through the center core (20G).  The cellulose 
solution and deionized water were extruded into a deionized water bath where the cellulose 
solution precipitates in the form of a porous hollow fiber (Figure 31).  Cellulose and water flow 
rate were varied according to Table 1 for the purpose of fabricating fibers with varying pore 
morphology.  Lyophilized hollow fiber cross sections were sputter coated with 3.5nm of gold-
palladium and imaged at 5kV using a JEOL 9335 SEM. 
10.3.2 Hollow fiber image analysis and characterization 
Scanning electron microscopy images were taken of three representative cross-sections of each 
fiber.  Using Metamorph software, measurements of wall thickness, macro-pore dimensions, 
micro-pore dimensions and porosity, were taken of each cross-section.  These measurements 
were used to characterize each fiber fabrication condition described in Table 1, and used to 
calculate model parameters described in Section 10.2.313 
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Figure 33.  Hollow fiber fabrication schematic. 
Polymer solution is 20% cellulose acetate solution and antisolvent is deionized water. 
 
 
 
Table 1.  Hollow fiber fabrication conditions. 
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10.3.3 Release studies 
Wells of a 6-well cell culture plate were filled with 5 mL Dulbecco’s phosphate buffered saline, 
or PBS (Invitrogen), supplemented with 1% bovine serum albumin (BSA).  Recombinant human 
VEGF, rh-bFGF and rm-PDGF (R&D Systems) was reconstituted using 1% BSA in PBS at 
various concentrations ranging from 0-200µg/mL.  Cellulose hollow fibers cut at 10cm were 
injected with 30µL of growth factor solution and submerged in the 5mL PBS (1% BSA) and 
place on a shaker.  At 10 time points over a 24 hour period, a sample of the PBS bath was taken, 
and the fiber was removed from the PBS bath and placed in a fresh PBS bath.  This process was 
repeated for each fiber/growth factor/concentration combination.  Growth factor concentration of 
each sample taken was measured using an ELISA kit (R&D Systems). 
10.3.4 Osmolality determination 
Osmolality measurements were recorded for varying concentrations of bFGF (31.25µg/mL, 62.5 
µg/mL, 125 µg/mL, 250 µg/mL), VEGF (41.67 µg/mL, 83.33 µg/mL, 250 µg/mL) and PDGF 
(12.5 µg/mL, 25 µg/mL, 50 µg/mL, 100 µg/mL) using an osmometer (Precision Systems 
Osmometer, Model 5004).  These values were used to calculate osmotic pressure differences 
across the hollow fiber wall when a concentrated solution of protein is injected into the lumen of 
the hollow fiber that is placed in a saline bath (see Section 10.3.3). 
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10.4 RESULTS 
10.4.1 Hollow fiber characteristics 
Hollow fibers fabricated according to conditions described in Table 2 reveal distinct differences 
in macro- and micro-pore morphology.  Measurements of fiber and macropore geometry were 
taken from SEM images similar to those shown in Figure 32.  Table 2 shows the measurements 
from the SEM image analysis, with calculated j1 based on measured macro-pore area (macro-
pore area is estimated as length times width).  The effective diffusion coefficient is calculated 
from individual parameters (j1, j2, W, δ, ε) and represents the effective diffusivity, without 
accounting for the individual diffusivity of each molecule (See Equation 10).  These results 
reveal that release based on diffusion is linearly related to the microporosity of the fiber. 
 
 
 
 
Figure 34.  Representative fiber characterization images. 
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Equation 10  
  
 
 
Table 2.  Hollow fiber model parameters.  
 
 
 
 
10.4.2 Osmolality 
Measurements taken with an osmometer demonstrate that osmolality is a linear function of the 
protein concentration, in the concentration range that is utilized in this study (Figure 33).  The 
osmolality of bFGF is most dependent upon the concentration, whereas the osmolality of PDGF 
is least dependent upon the concentration, with little change at all.  
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Figure 35.  Osmolality of VEGF, bFGF and PDGF, as a function of concentration. 
 
 
10.4.3 Model predictions and release data 
Model predictions were made with 10% variation in microporosity, injection volume, macropore 
geometry and fiber wall thickness, in order to observe the effect that changes in these variables 
would have on predicted release.  Changes up to ±10% in the microporosity did not produce a 
noticeable change in the release rate of an example protein VEGF.  Changes up to ±10% in the 
injection volume has a noticeable effect on the rate of release and thus time until complete 
release (Figure 34), with about a 0.27 hour change in complete release of protein, when εsp=0.1, 
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W=99.67µm, δ=84.08µm, j1=0.311 and injection concentration of VEGF=100µg/mL.  Changes 
up to ±10% in the fraction of j1 (the fraction of particles that travel through the microporous area 
only) also has a noticeable effect on the rate of release (Figure 35).  The theoretical change in j1 
predicts about a 0.33 hour change in complete release of protein, when εsp=0.1, W=99.67µm, 
δ=84.08µm, Vhf=0.01 and injection concentration of VEGF=100µg/mL.  Lastly, changes up to 
±10% in the fiber wall thickness have a noticeable effect on the rate of release (Figure 36).  The 
theoretical change in W predicts about a 0.6 hour change in complete release of protein, when 
εsp=0.1, j1=0.311, δ=84.08µm, Vhf=0.01 and injection concentration of VEGF=100µg/mL. 
 
 
 
 
 
Figure 36.  Effect of injection volume on release. 
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Figure 37.  Effect of micropore/macropore fractions on release. 
 
 
 
 
 
Figure 38.  Effect of wall thickness on release. 
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First, in vitro release data was compared to model predictions on an individual basis 
(Figure 39).  When an injection of 100µg/mL PDGF was injected into Fiber II (Figure 39, left) 
and when and injection of 100µg/mL VEGF was injection into Fiber I (Figure 39, right), the 
model matches the empirical release data well. 
 
 
 
 
 
Figure 39.  Model prediction and in vitro data. 
Fraction released versus time for protein from cellulose hollow fibers.  Blue line represents 
model prediction and red squares represents in vitro data for an injection of 100µg/mL PDGF in 
Fiber II (left) and 100µg/mL VEGF in Fiber I (right). 
 
 
 
Next, release of bFGF was compared, keeping the injection concentration the same 
(200µg/mL), but varying the physical properties of the fiber (Table 2).  Results of both model 
predictions and in vitro release can be seen in Figure 37.  Fiber III predicts (as well as in vitro 
data) the fastest rate of release (showing the shortest time until depletion of the lumen reservoir), 
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while Fiber II (as well as in vitro data) predicts the slowest rate of release (showing the longest 
time until depletion of the lumen reservoir). 
 
 
 
 
Figure 40.  Model prediction and in vitro data for bFGF release from Fiber I, Fiber II and 
Fiber III. 
Fraction released versus time for bFGF from cellulose hollow fibers fabricated under varying 
conditions.  Blue line represents model prediction for Fiber I (fabricated with water flowing at 
8mL/min and cellulose at 1.5mL/min).  Blue squares represent release data for Fiber I.  Red line 
represents model prediction for Fiber II (fabricated with water flowing at 13mL/min and 
cellulose at 2.5mL/min).  Red diamonds represent release data for Fiber II.  Green line represents 
model prediction for Fiber III (fabricated with water flowing at 10mL/min and cellulose at 
1.5mL/min).  Green triangles represent release data for Fiber III. 
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Release was also compared by varying the growth factor used, but consistently using 
Fiber III (fabricated with water flowing at 8.5mL/min and cellulose flowing at 1.5mL/min).  
Results of both model predictions and in vitro release can be seen in Figure 38.  In the first hour, 
release of VEGF reaches about 75%, while release of PDGF only reaches about 50%, but over 
the next 0.5 hours, VEGF release is only about 5%, while PDGF continues to release another 
25%.  Additionally, at 1.5 hours the fraction of bFGF released exceeds the fraction of VEGF 
released. 
 
 
 
Figure 41.  Model prediction and in vitro data for VEGF, bFGF and PDGF, release from 
Fiber III. 
Fraction released versus time for VEGF, bFGF and PDGF, from cellulose hollow Fiber III 
(fabricated with water flowing at 8mL/min and cellulose at 1.5mL/min).  Blue line represents 
model prediction for release of VEGF injected at 100µg/mL.  Blue squares represent release data 
for release of VEGF injected at 100µg/mL.  Red line represents model prediction for release of 
bFGF injected at 200 µg/mL.  Red diamonds represent release data for release of bFGF injected 
at 200 µg/mL.  Green line represents model prediction for release of PDGF injected at 50 µg/mL.  
Green triangles represent release data for release of PDGF injected at 50 µg/mL. 
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10.4.4 Model prediction for long term release 
The advantage of this model is that release profiles can be predicted without carrying out a 
bench-top study.  Injection concentration and volume can be readily changed, while the fiber 
wall geometry is a result of the hollow fiber fabrication process.  Figure 34 - Figure 36 reveals 
that injection volume, macropore geometry and fiber wall thickness, all have an effect on the 
release profile of an example protein VEGF, with as little as a 10% change.  In order for the 
model developed in this study to be used in a way that would allow for a greater impact on 
physiological processes, fibers with micropore and macropore geometry other than those 
represented in Table 2 would need to be developed.  If a hollow fiber could be fabricated so that 
j1=0.75, W=0.01cm, δ=0.008cm and εsp=0.1, and 100µg/mL of VEGF is injected, the model can 
predict release for varying injection volumes (0.01mL, 0.03mL and 0.05mL).  Figure 39 
represents model predictions for the aforementioned fiber parameters and injection 
characteristics, demonstrating that injection volume can play a large role in the release profile of 
VEGF.  For instance, increasing the injection concentration by 0.02mL can increase the time 
before termination of release by approximately 50 hours, which is a physiologically relevant time 
frame.  
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Figure 42.  Long term release predictions for VEGF, with varying injection volume (Vhf). 
 
10.5 DISCUSSION 
Although traditionally used for filtration purposes, hollow fibers have recently emerged in the 
drug delivery field, where proteins involved in bone growth265, aneurysm healing266 and 
neovascularization264 have been delivered.  Additionally, the need for fine control over growth 
factor delivery timing is becoming more important, as the scientific community learns more 
about the timing and sequence of growth factor involvement in biological processes.1, 189-192  The 
methods described in Sections 8.2.3 and 9.2.3 is intended to make steps toward analyzing release 
of angiogenesis promoting factors from cellulose hollow fibers. 
An externally-regulated hollow fiber delivery model can aid in the development of future 
therapies where growth factor timing is important, as this method can test a variety of release 
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schedules without complex changes to the release formulation.  The model described in this 
study is a step towards more accurate predictions of release from a porous hollow fiber, given the 
concentration and diffusivity of the injected protein in addition to hollow fiber geometry 
measurements.  This information allows for the calculation of the effective diffusivity, osmotic 
pressure difference across the fiber wall and solvent flux, which all contribute to the transport of 
proteins from the lumen of the hollow fiber to the surrounding environment. 
Through in vitro studies, it was determined that protein transport through a hollow fiber 
wall is not based on diffusion alone.  Equation 7 predicts that diffusive mass transport flux alone 
would set the time required to reach complete release (0.01mL injection of 200µg/mL, fiber 
8/1.5) on the order of weeks.  For this reason, other likely means of mass transport of protein 
across the hollow fiber wall were explored.  Although the charge and resulting isoelectric point 
can have an effect on the osmolality of a highly concentrated protein solution, it was discovered 
that the excipient with which the protein was lyophilized during the manufacturer’s isolation 
process had the greatest effect on protein contribution to osmolality.  For instance, an excipient 
with a low contribution to osmolality resulted in a small relationship between osmolality and 
concentration (ex: PDGF), and an excipient with a high contribution to osmolality resulted in a 
large relationship between osmolality and concentration (ex: bFGF).  Specifically, PDGF was 
lyophilized with 40% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid, contributing slightly 
to the osmolality (Figure 33, blue diamonds).  VEGF was lyophilized from PBS, contributing 
moderately to the osmolality (Figure 33, red squares).  Basic FGF was lyophilized with 20mM 
Tris and 1000mM NaCl, contributing greatly to the osmolality (Figure 33, green triangles).  The 
contribution that each of these excipients make to the osmolality of the solution injected into the 
hollow fiber results in the osmotic pressure difference between the lumen and surrounding 
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environment and consequent osmosis into the fiber.  Osmotic-driven solvent flux plays a role in 
the inevitable hydrostatic pressure increase within the fiber and ultimate protein transport.   
In Figure 38, it is observed that the predicted release rate (as well as measured in vitro 
release) of VEGF (blue) decreases after about an hour.  Based on the model described in this 
study, this decrease is likely due to a decrease in osmotic pressure difference (due to protein 
release), causing a decrease in overall solvent flux out of the fiber.  In contrast, the predicted 
release rate (as well as measured in vitro release) of bFGF (red) does not decrease in the time 
that it takes for all of the lumen contents to be released.  In agreement with this data, our model 
predicts that the greater osmolality dependence on bFGF concentration (versus VEGF 
concentration) as well as the higher injection concentration does not predict a osmotic pressure 
drop great enough to slow down the release rate within the time it takes for all of the contents of 
the fiber to be released (Figure 38).  Similarly, and in accordance with our experimental data, our 
model does not predict a noticeable decrease in the PDGF release rate over the time period 
observed in vitro (red) due to the relatively insignificant osmotic pressure dependence on PDGF 
concentration. 
Fiber characteristics such as microporosity, macropore geometry and wall thickness, all 
factor into the rate of protein transport across the hollow fiber membrane wall.  In terms of 
diffusion, it was found that the microporosity played the largest role in transport, where a linear 
relationship could be determined between the effective diffusivity coefficient and microporosity 
(Table 2).  A linear relationship could not be determined for any other measured hollow fiber 
characteristic.  In terms of solvent flux, macropore geometry and wall thickness, both of which 
play a role in osmotic and hydrostatic pressure based flow, were found to play a significant role 
in protein transport (Figure 35 and Figure 36).  However, microporosity, which only plays a role 
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in osmotic pressure based flow, did not have a significant effect on release.  In addition, there 
was also a correlation between the volume of injected protein solution and overall release during 
our experimental timeframes (Figure 34). 
Although macropore geometry, injection volume and wall thickness, each have a greater 
affect than microporosity on the overall release, a greater change than predicted in those cases 
(less than the one hour, Section 10.4.3) would make a bigger impact on a physiologic process.  
For example, using the process of angiogenesis as an example, our prior studies (Chapter 8.0  
and Chapter 9.0 ) suggest that delivery of an early stage factor would ideally be delivered for 
three days prior to a switch to delivery of a late stage factor for four days.281  In order for 
changes in release to make an greater impact on a physiological process, a significant decrease in 
release rate would need to occur.  As mentioned above, one way that this could occur would be 
to completely remove release due to convection by creating a high concentration protein solution 
with the same osmolality of saline (ex: a protein purified without excipients), where release 
based on diffusion can be on the order of weeks.  Another way for this to occur would be to 
decrease the size of the macropores, thus increasing the overall area that is only microporous (j1).  
Our model suggests that such a change would have a significant effect on release, due to the 
strong relationship between solvent flux (via the filtration coefficient) and macropore area.  If 
solvent flux is reduced by a decrease in macropore size, a significant decrease in the rate of 
release is observed (as seen in Figure 39).  This model can be used to determine the ideal fiber 
parameters and injection characteristics for the release of proteins according to a specific 
schedule. 
Future work has the potential to improve the accuracy of this model.  Currently, this 
model takes into consideration the protein diffusivity, injected concentration and many geometric 
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measurements of the hollow fiber.  However, it does not take into consideration other factors 
such as protein/fiber interactions and exact determination of reflection and filtration coefficients.  
It is possible that the lacking of these details is why the model can only predict release trends 
(Figure 38, green) in some cases.  For this specific example, the predicted time for complete 
release is underestimated by about 0.5 hours.  The data presented here is also limited to the 
specific proteins and release conditions explored in this study.  In order predict release of any 
protein under any release condition, it would be necessary to observe release under varying 
conditions and how these variations affect the transport of proteins across the hollow fiber wall. 
For example, because it would be extremely difficult to determine the exact concentration of 
these excipients in each solution, it would be necessary to isolate the protein completely from its 
excipients, through dialysis, before drawing any further conclusions of the transport of proteins 
across the hollow fiber membrane. Lastly, it would be necessary to explore hollow fiber 
fabrication techniques so that hollow fibers with smaller macropores can be fabricated. 
10.6 CONCLUSION 
A new model for predicted release from hollow fiber membranes has been developed.  This 
model attributes transport from the lumen of the hollow fiber to the surrounding environment to 
not only diffusion but convection caused by solvent flux, as well.  Using the equations described 
here, it is possible to predict release of VEGF, bFGF and PDGF, from a cellulose hollow fiber, 
after determination of specific characteristics of the hollow fiber.  The conclusions drawn here 
are the result of the specific experiments performed in this study.  Following further 
experimentation, the findings in this study support future use of this model as a design tool, 
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allowing researchers to rapidly acquire the hollow fiber design specifications necessary for a 
desired release profile. 
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11.0  SUMMARY AND CONCLUSIONS 
Sequential delivery strategies hold tremendous potential in the fields of tissue engineering and 
regenerative medicine where stage-wise processes are ubiquitous.  The hollow fiber-based 
delivery system described here can be used to explore the delivery of a wide variety of proteins 
as well as a wide variety of specific applications.  In this specific example, sequential delivery of 
angiogenesis promoting factors was explored in a murine Matrigel plug model, where 
endothelial cell migration, vasculature integration and vessel maturation, were explored.  When 
VEGF was delivered before S1P, we observed a statistically significant increase in both 
endothelial cell migration as well as vessel maturation, when compared to all other delivery 
schedules.  We also observed the most integration between newly formed vasculature and 
existing vasculature when VEGF was delivered before S1P.  When bFGF was delivered before 
PDGF, we also saw a statistically significant increase in both endothelial cell migration as well 
as vessel maturation, when compared to all other delivery schedules.  When examining vessel 
integration, it was discovered that the delivery of PDGF may aid in the formation of tubule 
structures, but only when bFGF was delivered before PDGF did we consistently see integration 
between newly forming vasculature and existing vasculature. 
In addition to investigating an in vivo response to sequentially delivered angiogenesis 
promoting factors, growth factor release from the hollow fiber membrane was explored.  It was 
determined that transport from the lumen of the hollow fiber to the surrounding environment can 
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be described not only by diffusion but by osmosis-driven convection as well.  Because the 
excipient used in the protein purification process increases the osmolality of a highly 
concentrated recombinant growth factor solution, an osmotic pressure difference exists between 
the lumen of the hollow fiber and the surrounding environment.  This results in an influx of 
water into the fiber, decreasing lumen concentration while increasing the hydrostatic pressure of 
the fiber.  Ultimately, the bulk solute flux out of the fiber due to solvent flow led to protein 
transport at a faster rate than diffusion alone. 
A model accounting for both diffusion and convection of recombinant protein was 
developed, allowing not only for prediction of release from cellulose hollow fiber membranes, 
but design of alternative hollow fiber membranes that can achieve release for a longer period of 
time.  This model can now be used as a tool for the development of fibers for delivery schedules 
for a broad range of applications.  The hollow fiber system as a whole can be used to explore any 
number of delivery schedules, allowing for a facile way to explore different delivery schedules 
of growth factors in vivo for therapeutic responses as well as for studying the basic biological 
signals that accompany stage-wise regeneration of tissues. 
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12.0  FUTURE WORK 
The work described here is a stepping stone toward the development of therapeutics in the 
medical field by demonstrating the importance of growth factor delivery timing.  At the very 
least, the hollow fiber delivery system can be used to explore various delivery schedules in order 
to probe an ideal delivery regime for a specific application.  This delivery schedule can then be 
applied to emerging temporal controlled release systems, such as the ones described in Chapter 
7.0 (combined release systems, layer-by-layer films, microchips and tunable microparticles).  
One example of an additional physiological system in which sequential delivery of growth 
factors can advance medical treatment is bone healing and de novo bone formation.325-326  Bone 
morphogenetic protein-2 has been identified as playing an important role in the development of 
bone and cartilage and has even been approved by the Food and Drug Administration for the 
treatment of bone healing in combination with a collagen scaffold (Infuse®).  However, PDGF 
has also been shown to play an important role in the early stages of bone healing, initiating both 
angiogenesis and proliferation of pre-osteoblasts at a wound site.  Externally controlled hollow 
fiber drug delivery can be used to explore various delivery schedules in a bone healing model, 
such as the rabbit cranial defect model, where a critical size defect is created in the skull of a 
rabbit.  In this model, due to the size of the defect and the area to which an individual hollow 
fiber can deliver proteins, it might be necessary to explore the use of multiple hollow fibers in 
series to achieve a clinically significant therapeutic outcome. 
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Externally controlled hollow fiber drug delivery can also be explored as a potential 
therapeutically relevant delivery system if hollow fibers with similar mechanical properties and 
pore geometry can be formed from triggerably degradable materials.  For example, incorporation 
of n-isopropylacrylamide into the backbone of a biocompatible polymer can cause a polymer to 
be water soluble at cold temperatures, but insoluble in water at body temperature.  Using this 
property, hollow fibers created from such a material can be used in vivo until the therapy is 
complete, at which point cold saline can be used to “wash away” the hollow fiber.  Such could 
possibly leave only newly formed tissue and obviate the need to surgically remove the delivery 
system. 
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